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ABSTRACT  
Alzheimer’s disease (AD) is characterized clinically by a progressive decline in 
cognition, and histopathologically by the presence of senile plaques (consisting mainly of 
amyloid-β, Aβ)  and neurofibrillary tangles in the brain, and the degeneration of basal forebrain 
cholinergic neurons.  Aβ, a 39-43 amino acid long peptide, is derived by proteolytic processing 
from its precursor, the amyloid precursor protein (APP).  Growing evidence indicates that the 
accumulation and deposition of Aβ in the brain, which may result from overproducion due to 
APP mismetabolism, or/and a failure in the clearance, is central to the pathogenesis of AD.  In 
recent years, a number of in vitro and in vivo studies have suggested that cholinergic 
neurotransmission may be involved in the regulation of APP metabolism.  However, the two 
questions raised by these findings, i.e. whether cholinergic dysfunction would lead to an 
increased Aβ production and thus deposition of Aβ in AD brain, and whether this process could 
be prevented by restoring or enhancing cholinergic activity, have not yet been studied in an in 
vivo model of AD.  In addition, the question regarding the pivotal role of Aβ overproduction 
and/or deposition in the development of cognitive impairments in AD needs to be further 
addressed in a suitable disease model.  
 In the present study we used APPswe and PS1(A246E) double transgenic mice (AP 
mice) as an AD model.  These mice develop the first amyloid deposits around the age of 9 
months and age-related cognitive deficits at a later age.  In these mice, we manipulated the level 
of acetylcholine (ACh) by two methods, 1) by treatment with a cholinesterase inhibitor, 
metrifonate, to increase the level of ACh, or 2) by fimbria-fornix lesion, to lower the ACh level 
in the hippocampus, in order to investigate the consequences of these changes on APP 
metabolism and Aβ deposition. In addition, we investigated the relation between the cognitive 
deficits and Aβ overproduction and/or deposition in these mice.   
We demonstrated that neither an increase nor a reduction in the level of ACh 
significantly affected APP metabolism, Aβ production and the deposition of Aβ.  Our results do 
not support the idea that cholinergic dysfunction would promote the process of Aβ production 
and deposition, or that an enhancement in cholinergic activity would slow down the progression 
of amyloid pathology in AD; conversely they indicate that APP metabolism may not be 
regulated by the level of ACh, at least in the AP mice that were used in our studies.  In the AP 
mice, the early amyloid deposits are largely restricted to the dorsal hippocampal formation; 
accordingly the mice showed a selective impairment in hippocampal-dependent long-term 
spatial memory.  Furthermore, the impaired memory significantly correlated with the amount of 
insoluble Αβ42, but not that of soluble Αβ42 in the hippocampus, or the Aβ levels in the CSF 
and serum.  Together, these findings support the role of insoluble Αβ42 in the development of 
memory impairments in AD.  
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Knowledge is power. 
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1. INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly 
(Evans et al., 1989).  The characteristic pathological features of AD include senile (i.e. 
neuritic) plaques, neurofibrillary tangles, and the degeneration of basal forebrain 
cholinergic neurons (Terry et al., 1999; Geula and Mesulam, 1999).  The core of senile 
plaques consists mainly of amyloid-β (Aβ) (Glenner and Wong, 1984; Masters et al., 
1985), a predominantly 39-43 amino acid long peptide derived by proteolytic 
processing from its precursor, the amyloid precursor protein (APP) (Robakis et al., 
1987; Tanzi et al., 1987).  
APP is proteolytically processed via alternative pathways.  The cleavage of APP 
by the α-secretase occurs within the Aβ domain, generating a large secreted form of 
APP (sAPP-α) and leaving a 83 amino acid long membrane-retained C-terminal 
fragment (Esch et al., 1990), and this will therefore preclude the formation of Aβ.  The 
Αβ peptides are produced when APP has undergone two sequential cleavages by the β- 
and γ-secretase, and this also produces a secreted APP derivative (sAPP-β) (Selkoe, 
2001).  Multiple lines of evidence indicate that an aberrant APP metabolism leads to 
overproduction and, eventually, deposition of Aβ in the brain, the process that is 
considered to be central to the pathogenesis of AD (Selkoe, 2001).   
In recent years, a number of studies have suggested that cholinergic 
neurotransmission may be involved in the regulation of APP metabolism (reviewed by 
Roberson and Harrell, 1997, and Rossner et al., 1998).  It has been demonstrated in 
vitro that stimulation of M1 and M3 acetylcholine receptors with muscarinic receptor 
agonists or treatment with cholinesterase inhibitor (ChEI) greatly increases the release 
of secreted APP from cultured cells or brain slices, thereby leading to reduced formation 
of Aβ, presumably by the activation of the α-secretase pathway (e.g. Nitsch et al., 1992; 
Mori et al., 1995b; Pakaski et al., 2000; Nitsch and Growdon, 1994).  On the other hand, 
cholinergic deafferentation in animals was shown to result in an elevated APP 
expression or production in the cerebral cortex or hippocampus (e.g. Wallace et al., 
1993; Leanza, 1998; Lin et al., 1998), though whether this would lead to increased 
production of Aβ, and Aβ deposition has not yet been clarified due to a lack of in vivo 
AD models (Beach et al., 2000; Boncristiano et al., 2002).  Together, these findings 
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imply a role of cholinergic dysfunction in the promotion of Aβ production, and, further, 
a potential neuroprotective effect of ChEIs or muscarinic receptor agonists in preventing 
the disease progress by restoring or enhancing cholinergic activity; these questions 
warrant further investigation in a suitable in vivo model of AD.   
Aggregated Αβ has been suggested to be neurotoxic by many studies (Lorenzo 
and Yankner, 1996; Harkany et al., 2000); however, the relation between amyloid 
deposition and cognitive impairments in AD is still controversial.  It was shown by 
several studies that the loss of synapses but not the number of amyloid plaques 
correlates with cognitive deficits in AD (reviewed by Terry et al., 1999).  In contrast, 
several recent studies have suggested that the number of amyloid plaques or the Aβ load 
does correlate with cognitive dysfunction (Cummings and Cotman, 1995; Cummings et 
al., 1996; Haroutunian et al., 1998; Kanne et al., 1998; Parvathy et al., 2001). In 
addition, the role of soluble Aβ behind the dementia symptoms was also emphasized by 
recent human neuropathological data (McLean et al., 1999). With the advent of new 
therapeutic approaches, such as immunization against Aβ (Schenk et al., 2001), 
treatment with amyloid β-sheet breakers (Soto et al., 1998), and with β- and γ-secretase 
inhibitors (Ghosh et al., 2002; Wolfe, 2002), it becomes essential to determine the role 
of Aβ in the development of cognitive impairments in AD.  
During the last several years, many groups have generated transgenic mouse 
models that develop amyloid deposits and cognitive deficits with age (Janus and 
Westaway, 2001; Price and Sisodia, 1998), providing an opportunity to directly study 
the factors that are involved in amyloid deposition and cognitive deficits.  In the present 
study, we have used APPswe and PS1(A246E) double mutant transgenic mice (AP 
mice) (Borchelt et al., 1997) as an AD model.  We manipulated the levels of ACh by 
using metrifonate, a second generation ChEI, and further we transected the fimbria-
fornix in these mice, to investigate the consequences on APP metabolism and amyloid 
deposition in the hippocampus.  In addition, we also investigated the relation between 
Aβ overproduction, deposition and cognitive decline in these AP mice. 
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2. REVIEW OF THE LITERATURE 
2.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) was named after the German physician Alois 
Alzheimer, who reported in 1907 a case of a presenile dementia in a 51-year-old woman 
(Alzheimer, 1907).  Since the late 1960s, AD has gradually been recognized as the most 
common cause of senile dementia (Selkoe, 2001).  Currently, AD accounts for about 50 
to 60% of the cases of cognitive impairment in elderly patients (Lobo et al., 2000; von 
Strauss et al., 1999).  The prevalence of AD increases after the age of 60 from about 1% 
among the 60- to 64-years-old to up to 40% of those aged 85 years and older (von 
Strauss et al., 1999).  
2.1.1. Clinical features of AD 
Clinically, AD is characterized by a progressive loss of cognitive abilities.  The 
majority of patients exhibit dementia after 60 years of age, while a small portion of 
patients with familial AD (FAD) often become demented in their midlife (Price and 
Sisodia, 1998).  The memory impairment is selective as to the type and its time span. 
Declarative memory, i.e. the conscious recollection of facts and events, is affected; 
whereas procedural memory, i.e. the memory for skills and habits, is largely intact 
(Forstl and Kurz, 1999; Rossor et al., 1996; Squire and Zola, 1998).  Further, memory 
for recent events that occurred in a particular spatial and temporal context, i.e. episodic 
memory, declines early in the course of the disease; whereas semantic memory for 
general facts is impaired only later in the disease (Almkvist, 1996; Rossor et al., 1996; 
Squire and Zola, 1998).  Gradually, language impairments, visual perceptual and spatial 
deficits, agnosias and apraxias emerge as the disease progresses (Rossor et al., 1996). 
Meanwhile, the patients are also increasingly impaired in their daily living activities, 
and in late stages of AD, patients often become mute, incontinent, and bedridden (Price 
and Sisodia, 1998). 
2.1.2. Neuropathological features of AD  
The definite diagnosis of AD requires neuropathological examination of the 
brain at autopsy.  The currently used diagnostic criteria of AD are based on either the 
assessment of amyloid plaque frequency (i.e. NIA criteria, Khachaturian, 1985 and 
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CERAD, Heyman et al., 1990), or neurofibrillary pathology stageing (Braak and Braak, 
1991), or both (The National Institute on Aging, and Reagan Institute Working Group 
on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease, 
1997).  Macroscopic changes found in late AD brains include shrinkage of the gyri and 
widening of the sulci especially in medial temporal lobes, and enlargement of the 
ventricles; and the two major microscopical lesions are extracellular amyloid plaques 
and intracellular neurofibrillary tangles (Esiri, 2001).  In AD, progressive 
neurodegeneration starts from the medial temporal lobe, i.e. the entorhinal cortex, 
hippocampus and subiculum, and later extends to other neocortical regions, particularly 
association areas, as well as subcortical areas, such as the basal forebrain cholinergic 
system, and several brain stem monoaminergic nuclei (Price and Sisodia, 1998; Geula, 
1998). 
 2.1.2.1. Amyloid plaques  
Two major types of amyloid plaques are recognized in the brain of AD patients 
(Terry et al., 1999), i.e. neuritic and diffuse plaques.  The classical neuritic plaque is a 
small, spherical structure with a 50 to 200 µm diameter, which has a dense amyloid core 
and is surrounded by dystrophic neurites (Cummings et al., 1998b).  Reactive astrocytes 
and microglia are found in the plaque periphery and around the plaque (Cummings et 
al., 1998b).  Most of the Αβ found in neuritic plaques is the 42 amino acid long form of 
Aβ (i.e. Αβ42), with the 40 amino acid long Αβ40 co-localized (Selkoe, 2001).  In 
contrast, diffuse plaques, the second type of amyloid plaque, do not contain an amyloid 
core and are not surrounded by dystrophic neurites (Cummings et al., 1998b).  The 
amyloid deposits in the diffuse plaques are non-fibrillar (Selkoe, 2001) and are almost 
comprised exclusively of Aβ42, with little or no Aβ40 present (Iwatsubo et al., 1994).  
2.1.2.2. Neurofibrillary tangles  
Many brain regions that are typically affected early in AD contain large numbers 
of neurofibrillary tangles, such as the entorhinal cortex, hippocampus, parahippocampal 
gyrus, and amygdala (Selkoe, 2001).  These tangles consist of pairs of ~10-nm filaments 
twisted into the form of paired helical filaments, and they occupy much of the 
perinuclear cytoplasm and may extend into the dendrites but do not occur in axons 
(Selkoe, 2001).  The filaments are composed of the microtubule-associated protein tau, 
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which is abnormally hyperphosphorylated (Grundke-Iqbal et al., 1986; Kosik et al., 
1986; Wood et al., 1986).  Since hyperphosphorylated tau binds poorly to microtubules 
and thus alters their stability, these modifications of tau could disrupt intracellular 
transport, cellular geometry, and neuronal viability, eventually causing cell death (Price 
and Sisodia, 1998).  Large pyramidal cells are the neurons that mostly develop 
neurofibrillary tangles, particularly those with long cortico-cortical connections 
(Cummings et al., 1998b).   
2.1.2.3. Neuronal loss and synaptic alterations 
Neuronal loss has been observed in a number of cortical and subcortical regions 
(Cummings et al., 1998b); within the neocortex, the frontal and temporal lobes are 
typically involved.  Further, in the early stages of AD pathology massive neuronal loss 
is regularly observed in the superficial entorhinal cortex (the major input of the 
hippocampus), and in the major hippocampal efferent area, i.e. the subiculum (Geula, 
1998).  Therefore, it has been suggested that the cognitive decline in AD is at least 
partially attributable to the functional isolation of the hippocampus (Geula, 1998).  In 
addition, the cognitive decline can also be related to the disruption of the structural 
integrity of synapses (Terry et al., 1999).  In the AD brain, presynaptic terminal density 
is significantly decreased in the neocortex, most remarkably in frontal cortex and 
hippocampus (Honer et al., 1992; Scheff et al., 1990; Terry et al., 1999).  Further, 
synaptic density is greatly decreased in regions with many neuritic plaques, but not 
diminished in areas with diffuse plaques (Masliah et al., 1990). 
2.2. Amyloid-β peptide and the pathogenesis of AD 
Αmyloid-β peptide (Aβ)  is  the main component of amyloid plaques (Glenner 
and Wong, 1984; Masters et al., 1985).  Based on genetic findings in FAD and 
observations in Down’s syndrome, the role of Aβ in the pathogenesis of AD has been 
formulated as the “amyloid cascade hypothesis” by Hardy and Higgins (1992)  a decade 
ago.  It proposes that a dysregulation in APP processing occurs early in the disease 
process, resulting in increased production of the highly self-aggregating Aβ42.  The 
aggregated Aβ is then supposed to induce all subsequent pathology, including tau 
hyperphosphorylation, tangle formation, and neuronal death.  
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2.2.1. APP metabolism and Aβ production 
Αβ is derived from its large precursor protein (i.e. APP) by proteolysis, and only 
a trace amount of Aβ  can be detected under physiological contitions (Haass et al., 
1992; Shoji et al., 1992; Seubert et al., 1992).  However, an aberrant APP metabolism 
will lead to overproduction of Aβ, the process that has been suggested to be central to 
the pathogenesis of AD (Selkoe, 1997).  
APP is a single transmembrane domain protein, and it is ubiquitously expressed 
in a variety of tissues, including brain (Selkoe, 1999).  In human, there are three major 
isoforms that have 695, 751, and 770 residues, respectively (Figure 1A).  The two 
longer forms, APP751 and APP770 contain a 56 amino acid domain (Sinha and 
Lieberburg, 1999) that is homologous to a Kunitz-type of serine protease inhibitor (KPI) 
(Figure 1A).  APP751 and APP770 are widely expressed throughout the body, but in the 
brain it is mainly expressed by glial cells (Rohan de Silva et al., 1997).  APP695, which 
lacks the KPI domain, is the most abundant isoform in the brain and expressed 
predominantly by neuronal cells, with a very low level of expression in non-neuronal 
cells.  
APP has a short half-life (about 20-30 minutes) (Weidemann et al., 1989), and it 
is metabolized down two pathways after biosynthesis, either the non-amyloidogenic α-
secretase pathway or the amyloidogenic β-secretase pathway (Hardy, 1997).  Under 
normal circumstances the α-secretase pathway is predominant; it cleaves APP between 
amino acids 16 and 17 of the Aβ region, which therefore precludes the production of Aβ 
(Esch et al., 1990) (Figure 1A and B).  This cleavage creates a large, soluble 
ectodomain fragment (sAPP-α) that is subsequently released, and a membrane-retained 
C-terminal fragment (CTF) consisting of 83 amino acids (i.e. C83) (Selkoe, 2001).  A 
smaller amount of APP is processed by the β-secretase, which cleaves APP between 
residues 671 and 672 (Figure 1C).  This releases a slightly truncated form of sAPP 
(sAPP-β) from the cell (Schubert et al., 1989) and leaves a 99-residue CTF (i.e. C99) at 
the membrane.  The C99 can subsequently be cleaved by the γ-secretase at either 
residue 711 or residue 713 to create Aβ, and the site of cleavage by the γ-secretase 
determines whether the long or short form of Aβ (Aβ42 or Aβ40, respectively) is 
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produced (Hardy, 1997).  The C83 CTF produced by α-secretase can also undergo 
cleavage by the γ-secretase to generate the p3 peptides (Figure 1B) (Selkoe, 2001). 
γ-secretaseB.
18 687              711 or  713
sAPP- α C83
p3  
α-secretase
Aβ
γ-secretaseC.
18 671 711 or  713
sAPP- β C99
β-secretase
A.
TM
596                   695
COOH
APP695
Aβ
1 18
NH2
1 18 289                                        671         770
COOH
KPI                               Aβ
NH2
APP770
TM
  
Figure 1.  Schematic diagrams of the structure of the APP protein with the two 
pathways that process APP indicated.  (A). APP has a single membrane-
spanning domain (TM), and a 17-residue signal peptide at the N terminus. The 
diagram illustrates two APP alternate splice forms, which comprise 695 and  
770 amino acids, respectively (i.e. APP695 and APP770). APP770 contains a 
serine protease inhibitor domain of the Kunitz type (KPI).  (B) α-secretase 
cleaves APP after residue 687, resulting in the secretion of the large, soluble 
ectodomain of APP (sAPP-α) into the medium and retention of carboxy-
terminal fragment C83 in the membrane. The C83 fragment can undergo 
cleavage by γ-secretase at residue 711 or residue 713 to release the p3 peptides. 
(C) Alternatively, β-secretase cleaves APP after residue 671, resulting in the 
secretion of the slightly truncated sAPP-β, and the retention of C99, which can 
be further cleaved by γ-secretase at residue 711 or residue 713 to release the 
Aβ40 or Aβ42 peptides. (modified from a figure by Selkoe, 1999). 
 
 Despite intensive study, the functions of APP and its fragments are not yet very 
well understood.  Soluble sAPP-α appears to be capable of acting as an autocrine factor 
(Saitoh et al., 1989) and as a neuroprotective and neurotrophic factor (Mattson et al., 
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1993).  Further, APP has been suggested to function in cell-to-cell interactions (Qiu et 
al., 1995).  However, most of these functions have not yet been confirmed in vivo.  On 
the other hand, mice with a targeted deletion of the APP gene appear to be relatively 
normal, perhaps because of the fact that they still express the amyloid precursor-like 
proteins (APLPs), which are homologous to APP (Slunt et al., 1994). 
2.2.2. Genetic mutations in AD 
Since the early 1990s, it has been shown that AD can be caused by autosomal 
dominant mutations in three genes: APP on chromosome 21, presenilin-1 on 
chromosome 14 (PS1) and presenilin-2 on chromosome 1 (PS2) (reviewed by Selkoe, 
2001).  These mutations are estimated to account for about half of the early-onset 
familial AD cases (FAD), i.e. about 2.5% of all AD cases (Blacker and Tanzi, 1998; 
Price et al., 1998).   
APP mutations typically lead to AD at about 45 to 60 years of age.  All 
mutations are located closely to the cleavage sites of either β-secretase or γ-secretase 
(Selkoe, 2001).  The “Swedish mutation”, a double mutation that occurs in the two 
amino acids immediately prior to the β-secretase cleavage site, induces increased 
production of both Aβ40 and Aβ42 by enhancing β-secretase cleavage (Citron et al., 
1992; Mullan et al., 1992; Selkoe, 2001).  The APP mutations all have in common that 
they lead to the production of more Aβ42 or to a change in the aggregation properties of 
Aβ (Hardy, 1997), thereby predisposing to the development of AD.  Studies of Down's 
syndrome strongly support the crucial role of Aβ in the pathogenesis of AD.  These 
patients overexpress normal APP due to an extra copy of chromosome 21 (Petronis, 
1999; Potter, 1991), and this leads to an overproduction of APP and Aβ (Tokuda et al., 
1997).  Almost invariably, Down’s syndrome patients first develop diffuse plaques, 
which solely consist of Aβ42, in their teenage years (Lemere et al., 1996) and 
eventually develop neuropathology that is very similar to AD by middle age. 
PS1 mutations account for most of the reported FAD cases and generally lead to 
an onset of AD before the age of 50 (Selkoe, 2001).  In contrast to PS1 mutations, 
mutations in PS2 are relatively rare (Sherrington et al., 1996).  PS1 and PS2 are 
transmembrane (TM) proteins with six to nine TM domains (Levy-Lahad et al., 1995; 
Sherrington et al., 1995), and they show a high degree of homology to each other, 
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especially in their putative TM domains.  Similar to APP, presenilins are also expressed 
ubiquitously, and the majority of the presenilin protein is cleaved to yield a ~25 kDa N-
terminal fragment and a ~19 kDa C-terminal fragment (Mercken et al., 1996; 
Thinakaran et al., 1996).   
PS1 has been proposed to play a role in protein trafficking within the cell 
(Naruse et al., 1998).  In addition, PS1 is needed for Notch-mediated signaling during 
embryogenesis (Ray et al., 1999); it has been shown that PS1 knockout mice display 
abnormalities in body segmentation (Conlon et al., 1995; Wong et al., 1997).  The 
effects of the presenilin mutations on APP metabolism have been well documented.  
Cells expressing the FAD mutant form of PS1 have an increased generation of Aβ42, 
thus increasing the potential for Aβ aggregation (Borchelt et al., 1996b; Citron et al., 
1997).  Correspondingly, transgenic mice expressing both the mutant forms of APP and 
PS1 demonstrate an accelerated rate of amyloide deposition presumably due to the 
increase of Aβ42 production (Borchelt et al., 1997; Holcomb et al., 1998). 
Taken together, common to all these genetic mutations is the property to 
increase the production of Aβ, especially Aβ42, or enhance Aβ aggregation in the brain.  
These observations suggest the causative role of Aβ in the pathogenesis of AD (Selkoe, 
2001). 
2.2.3. Aβ and the pathogenesis of AD 
The Aβ peptide mainly exists in two forms: as a soluble peptide or in an 
aggregated state as insoluble amyloid deposits, which can have the β-pleated sheet 
conformation (Selkoe, 2001).  The deposition of Aβ42 is considered to be an early event 
in AD, followed by the deposition of Aβ40 (Jarrett et al., 1993).  It has been suggested 
that the aggregated form of the Aβ peptide is the primary neurotoxic agent both in vitro 
(Pike et al., 1993; Lorenzo and Yankner, 1994) and in vivo (Giovannelli et al., 1998).  
The gradual accumulation and deposition of Aβ appear to activate adjacent microglia 
and astrocytes, with the concomitant release of cytokines and acute-phase proteins 
(McGeer and McGeer, 1995).  Subsequently, local neurons and their processes could be 
injured by the inflammatory response.  In addition, Aβ may further injure neurons by 
disrupting calcium homeostasis (Joseph and Han, 1992) or by inducing oxidative 
damage (Keller et al., 1997; Thomas et al., 1996).  The accumulation of Aβ  may also 
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induce or accelerate the phosphorylation of tau and thus the formation of paired helical 
filaments and NFTs (Selkoe, 2001).  Eventually, these pathological events could lead to 
synaptic loss, shrinkage of neuronal perikarya, neuronal dystrophy, and selective 
neuronal loss, as well as neurotransmitter deficits, including the basal forebrain 
cholinergic system (Selkoe, 2001). 
Although the neurotoxicity of aggregated Αβ has been suggested by many 
studies (Lorenzo and Yankner, 1996; Harkany et al., 2000), the correlation between 
amyloid plaques and cognitive impairments in AD is still controversial.  It has been 
shown by earlier studies that the loss of synapses but not the number of amyloid plaques 
correlates with cognitive deficits in AD (reviewed by Terry et al., 1999).  In contrast, 
several recent studies have shown that amyloid plaques do correlate with cognitive 
dysfunction (Cummings and Cotman, 1995; Cummings et al., 1996; Haroutunian et al., 
1998; Kanne et al., 1998).  However, in some transgenic AD mouse models, cognitive 
deficits occur in the absence of amyloid deposits (D'Hooge et al., 1996; Koistinaho et 
al., 2001; Moechars et al., 1999).  Further, Mucke et al. (2000) observed that mutant or 
wildtype human APP (huAPP) transgenic mice show loss of synapses regardless of 
whether amyloid deposits were present.  Together, these findings suggest that plaque-
independent Aβ neurotoxicity could also play an important role in the neuropathology 
of AD.  Recent studies suggest that such toxic effects might be attributed to the 
neurotoxicity of Aβ oligomers and protofibrils (Klein et al., 2001).  Further, it has been 
suggested that Aβ per se is only a marker for proteolytic cleavage of APP and that it is 
the transcriptionally active carboxy-terminal of APP itself that is involved in the 
pathogenesis of AD (Cao and Sudhof, 2001). 
2.2.4. Transgenic mouse models of AD  
Before the identification of AD-causing gene mutations, animal models of AD 
were limited to reproduce other aspects of neuropathology, such as neuronal loss or 
cholinergic depletion (Chapman et al., 2001).  Now, multiple lines of transgenic AD 
model mice have been created that have Aβ deposition and amyloid plaques, the key 
pathological hallmark of AD, as well as age-related learning and memory deficits (Janus 
and Westaway, 2001; Seabrook and Rosahl, 1999).  These transgenic mouse models 
offer new opportunities to investigate the biochemical and cellular mechanisms of this 
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disease, and also provide systems to test potential therapeutics (Price and Sisodia, 
1998).  APP transgenic mice include mice expressing wild-type huAPP751 on the 
mouse APP background (Buxbaum et al., 1993a), the truncated C-terminus of APP 
(Kammesheidt et al., 1992), and mutations associated with FAD including APP(V717F) 
(PDAPP mouse)(Games et al., 1995), APP695(K670N, M671L) (Tg2576 mouse) 
(Hsiao et al., 1996), and APP751(K670N,M671L) (Sturchler-Pierrat et al., 1997), etc.  
The PDAPP and the Tg2576 transgenic mice are most widely used APP single mutant 
AD models (see Table 1).  Most of these mice age-dependently overproduce Αβ and 
develop amyloid plaques, but none of these mice have been shown to display 
remarkable neuronal loss and formation of NFTs, which are also characteristic of AD 
(Chapman et al., 2001). 
PS1 transgenic mice overexpressing mutant forms of human PS1 transgene on 
the mouse PS1 background (Borchelt et al., 1996b; Citron et al., 1997; Duff et al., 1996) 
do not exhibit amyloid deposition, despite the increase of Αβ1-42/43 production and an 
elevated ratio of Aβ42 to Aβ40.  However, in APP and PS1 double mutant mice, the 
increase in the ratio of the highly amyloidogenic Aβ42 relative to Aβ40 is greatly 
enhanced compared with transgenic lines overexpressing either mutant APP or mutant 
PS1 alone (Borchelt et al., 1997; Citron et al., 1997; Holcomb et al., 1998).  
Accordingly, the neuropathology is greatly accelerated in double transgenic mice.  Mice 
expressing both APPswe and the PS1(M146L) mutation (Holcomb et al., 1998) show 
amyloid deposits in the cerebral cortex and hippocampus already at 13-16 weeks of age 
in comparison to 9-12 months in the single APPswe mouse line.  In the APPswe mouse 
line expressing a chimeric mouse/human (mo/hu) APP695 harboring a human 
Aβ domain and Swedish AD mutations, amyloid deposition was accelerated from 18 
months of age to 9 months of age when PS1(A246E) mutation is also present (Borchelt 
et al., 1997).  In this APP+PS1 mouse line (i.e. AP mice that we used), the formation of 
amyloid plaques starts in the hippocampus, subiculum and caudal cortex, and later 
extends to all cortical areas (Borchelt et al., 1997).   
Among the two APP+PS1 mouse lines, the APPswe and PS1(M146L) line has 
been extensively studied both histopathologically and behaviourally. Aβ deposition 
started primarily in the cingulate cortex of APP+PS1 mice at approximately 10 weeks of 
age, and by the age of 6 months extensive Aβ depostion can be detected in the 
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hippocampus and cortex (McGowan et al., 1999). The early Αβ deposits were found to 
be primarily composed of fibrillar Αβ and resembled compact amyloid plaques (Gordon 
et al., 2002).  As the mice aged, the fibrillar Aβ deposits remained restricted to cortical 
and hippocampal structures, while non-fibrillar Αβ deposits increased in number and 
spread to regions, such as striatum and cerebellum, that not typically associated with 
amyloid plaques in AD.  In these doubly transgenic mice, the diffuse deposits are 
primarily composed of Αβ42, while the compact deposits contain both C-terminal forms 
of the peptide. The fibrillar deposits were associated with dystrophic neuritis, and the 
activation of microglia and astrocytes (Gordon et al., 2002).  From the age of 5-7 
months to 15-17 months, a progressive cognitive impairment was observed in transgenic 
mice for both water maze acquisition and radial arm water maze working memory 
(Arendash et al., 2001).  In the radial arm water maze task, the performance of 
individual mice within the transgenic group was inversely correlated with the amount of 
Aβ deposited in the frontal cortex and hippocampus (Gordon et al., 2001), implying that 
APP+PS1 transgenic mice develop deficits in cognitive ability as Aβ deposits increase.  
However, transgenic mice did not show impairment in performing the tasks, such as Y-
maze alternations, circular platform performance, standard water maze retention, or 
visible platform recognition at either age (Arendash et al., 2001).  Compared with the 
APP+PS1(M146L) mice, the pathological and behavioural characteristics of the 
APP+PS1(A246E) mice (i.e. our AP mice) have been much less studied (Borchelt et al., 
1997).  
A comparison of histopathological and behavioural features of several 
representative transgenic mouse models of AD is shown in Table 1. 
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Table 1. Representative transgenic mouse models of Alzheimer’s disease 
 
 
      Tg mouse line         Construct   Neuropathology Learning and memory 
   APP Tg mouse    
Hsiao et al., 1996 
(Tg2576 mouse) 
HmPrP: APP695swe 
(K670N+M671L) 
Amyloid plaques  
( > 12 months) 
Astrocytosis 
Microgliosis 
No cell loss and NFT 
Deficits in Morris water 
maze 
Reduced spontaneous 
alternation performance 
in Y-maze 
Games et al., 1995 
(PDAPP mouse) 
PDGF: APPV717F Amyloid plaques 
( > 6 months) 
Astrocytosis 
Microgliosis 
Synapse loss 
No cell loss and NFT 
Hippocampal atrophy 
Deficits in modified 
water maze 
Deficits in a spatial 
discrimination learning 
task in radial arm maze 
Deficits in a 
spontaneous object 
recognition task 
 
Borchelt et al., 1997 MoPrP: APP695swe 
(K670N+M671L) 
Amyloid plaques  
( > 18 months) 
Astrocytosis 
Microgliosis 
No cell loss and NFT 
 
Not studied 
    PS1 Tg mouse    
Duff et al., 1996 
 
PDGF: PS1M146L  
and M146V 
Elevated Aβ42 level 
without amyloid plaque 
 
No cognitive deficits 
Borchelt et al., 1996 MoPrP: PS1A246E Elevated Aβ42 level 
without amyloid plaque 
No cognitive deficits 
 
 
 APP+PS1 Tg mouse   
Holcomb et al., 1998 
(APP+PS1M146L mouse) 
HmPrP: APP695swe 
(K670N+M671L) x 
PDGF: PS1M146L 
Amyloid plaques  
( >  3 months) 
Astrocytosis 
Microgliosis 
No cell loss and NFT 
Deficits in Morris water 
maze acquisition 
Deficits in radial arm 
water maze working 
memory 
Borchelt et al., 1997 
(APP+PS1A246E mouse) 
MoPrP: APP695swe 
(K670N+M671L) x 
PS1A246E 
Amyloid plaques 
( > 9 months) 
Astrocytosis 
Microgliosis 
No cell loss and NFT 
 
Not studied (subject of 
the present study) 
APP: amyloid precursor protein; PS1: presenilin 1; HmPrP: hamster prion protein promoter; 
MoPrP: mouse prion protein promoter; PDGF: platelet-derived growth factor promoter 
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2.3. Cholinergic system and AD 
2.3.1. Cholinergic degeneration in AD and cholinergic hypothesis 
In human, the basal forebrain cholinergic system consists of four cell groups that 
are located in the medial septum (MS-Ch1), the vertical and horizontal limb of the 
diagonal bands of Broca (VDB-Ch2 and HDB-Ch3, respectively), and the nucleus 
basalis of Meynert (NbM-Ch4) (Geula and Mesulam, 1999).  In the non-human primate 
(rhesus monkey), the MS-Ch1 and VDB-Ch2 neurons provide the major cholinergic 
innervation of the hippocampus, the HDB-Ch3 neurons provide the major cholinergic 
innervation of the olfactory bulb, and the NbM-Ch4 neurons provide the major 
cholinergic innervation of the entire cortical mantle and the amygdala (Mesulam et al., 
1983).  
A consistent feature of the AD brain at autopsy is the loss of basal forebrain 
cholinergic neurons (Davies and Maloney, 1976) that has been reported for all four 
cholinergic cell groups, with the NbM-Ch4 neurons affected most severely (Geula and 
Mesulam, 1999).  The loss of cholinergic neurons in the basal forebrain causes a 
dramatic reduction of ChAT activity (up to 95%) in the neocortex (e.g. Davies and 
Maloney, 1976 and Bowen et al., 1976) and hippocampus (e.g. Araujo et al., 1988), and 
it has been speculated that this would likely result in a marked decrease of acetylcholine 
(ACh) levels in above regions (Bartus et al., 1982).  Acetylcholinesterase (AChE), the 
enzyme responsible for the degradation of ACh, is also reduced in AD (Perry et al., 
1978).  In addition, changes in cholinergic receptors in AD have been reported. 
Muscarinic M1 receptors are relatively preserved in AD, whereas M2 and nicotinic 
receptors are significantly decreased (Geula and Mesulam, 1999).  Furthermore, the 
cognitive deficits induced by centrally active anticholinergic compound (i.e. 
scopolamine) in young human subjects somewhat resembled that seen in AD 
(Drachman and Leavitt, 1974).  Together, these observations formed the basis of the 
“Cholinergic hypothesis of AD”, which stated that the cholinergic dysfunction plays an 
important role in the memory loss and related cognitive problems (Bartus et al., 1982).  
However, later studies have suggested that the cognitive deficits in AD are unlikely to 
be caused solely by one neurotransmitter system, because selective lesioning of the 
cholinergic neurons in the basal forebrain by immunotoxin 192IgG-saporin does not 
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lead to significant learning and memory impairment but rather attention deficits in rats 
(Muir, 1997).  Other neurotransmitter systems that are affected by the disease, such as 
the glutamatergic, serotonergic and noradrenergic systems (Procter et al., 1988; Palmer 
et al., 1987; Mann, 1983), may also contribute to the cognitive deficits in AD.  
2.3.2. Cholinergic therapeutic strategy of AD  
The cholinergic hypothesis of AD has provided the rationale for the current 
major therapeutic approach to the disease, which is aimed to correct the cognitive 
decline by enhancing cholinergic neurotransmission.  Of the multiple possible strategies 
for enhancing cholinergic neurotransmission in the brain, cholinesterase inhibition has 
been so far the most extensively used.  Cholinesterase inhibitors (ChEI) prevent the 
hydrolysis of ACh, thus increasing cholinergic transmission by making more ACh 
available. Giacobini (2001) compared the therapeutic effects of six ChEIs (including 
metrifonate) based on the results of clinical studies in AD patients. All six ChEIs 
produced statistically significant but modest improvements in both cognitive and non-
cognitive function.  It is noteworthy that in the placebo group there is a continuing 
cognitive decline with little or no change in the drug-treated patients over the trial 
course. This observation suggests that ChEIs may possess cognitive stabilization effect 
via a mechanism of action other than symptomatic or directly cholinergic (Giacobini, 
2001). 
Metrifonate (MTF), a representative cholinesterase inhibitor of the second 
generation, is an organophosphorous compound (Figure 2), which is converted by a 
nonenzymatic process to the active AChE inhibitor 2,2-dichlorovinyl dimethyl 
phosphate (DDVP, Figure 2) (Hinz et al., 1996a; Hinz et al., 1996b).  DDVP binds to 
the active site of AChE and irreversibly inhibits the enzyme; therefore, the recovery of 
AChE is dependent on synthesis of new enzyme (Hinz et al., 1996b).  Although the 
elimination half-life of DDVP is 2-3 hours, the half-life of cholinesterase inhibition by 
DDVP is as long as 2 -6 days (Ringman and Cummings, 1999). Animal studies have 
demonstrated the efficacy of MTF in ameliorating learning and memory deficits in both 
rats (Riekkinen et al., 1997) and mice (Ikonen et al., 1999) that have lesions in the 
cholinergic system.  In double-blind, placebo-controlled studies in AD patients, MTF 
led to improvements of cognition or a reduced rate of decline of cognition compared 
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with placebo (Cummings et al., 1998a),  and it also benefited the global function of 
these patients (Morris et al., 1998).  However, adverse effects were noted in clinical 
trials, specifically a number of cases involving respiratory paralysis, caused the 
withdrawal of MTF from clinical trials. 
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Figure 2.  Schematic diagrams of the chemical structure of metrifonate 
(MTF), and its derivative dichlorovinyl dimethyl phosphate (DDVP). 
DDVP binds to the active site of the AChE and irreversibly inhibits the 
activity of the enzyme (re-drawn form a figure by Taylor, 1998). 
2.3.3. Cholinergic neurotransmission and APP metabolism 
Several lines of evidence suggest that modulating cholinergic neurotransmission 
can influence the metabolism of APP.  
First, stimulation of M1 and M3 receptors with muscarinic receptor agonists or 
ChEI greatly increases the production of secreted APP with concomitant decreases in 
Aβ generation.  It was first reported by Nitsch et al. (Nitsch et al., 1992), using cells that 
were stably transfected with human mAChRs (M1, M2, M3, M4), that carbachol, a non-
selective muscarinic receptor agonist, increased the amount of secreted APP released in 
cells expressing M1 and M3 receptors, but not in cells expressing the M2 or M4 
subtypes.  The increase of APP secretion could be blocked by the muscarinic antagonist 
atropine or by protein kinase C (PKC) inhibitors, suggesting that PKC mediates the 
receptor-controlled APP secretion.  In addition, increased APP secretion from rat brain 
slices and cell cultures was also observed after indirect activation of muscarinic ACh 
receptors via the inhibition of AChE (Mori et al., 1995b; Pakaski et al., 2000).  Further, 
increased APP secretion has been demonstrated to be associated with a reduction of Aβ 
generation.  Hung et al. (1993) have shown that in cell lines overexpressing mAChR 
and huAPP with AD-associated mutations, the increase in APP secretion after mAChR 
stimulation is accompanied by a 50% reduction in the release of soluble Aβ and by an 
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increase in the generation of the non-amyloidogenic p3 fragment.  Based on these 
findings, it was postulated that the activation of M1/M3 mAChR-associated signaling 
pathways enhances α-secretase activity but decreases β-secretase processing of APP 
(Nitsch and Growdon, 1994).  In addition, it should be noted that few studies reported 
that treatment with nicoitine, both in vitro and in vivo, could also modify APP 
processing by increasing the release of secreted form of APP (Kim et al., 1997; Lahiri et 
al., 2002). 
Second, a reduction in cholinergic neurotransmission has been linked to 
enhancesed APP expression/production, which may potentially lead to an increase in 
Aβ production.  In rats, excitotoxic lesions of the cholinergic basal forebrain or 
transection of fimbria-fornix have been reported to increase the levels of APP mRNA or 
APP immunoreactivity in the cerebral cortex, or hippocampus (e.g. Wallace et al., 1991; 
Wallace et al., 1993; Beeson et al., 1994).  Similarly, selective cholinergic lesions of 
basal forebrain have also been shown to increase APP gene expression or protein level 
in rats (Leanza, 1998; Lin et al., 1998) and in marmosets (Ramirez et al., 2001). 
However, whether an enhanced APP expression/production would lead to increased 
production of Aβ, and further the deposition of Aβ has not yet been clarified due to a 
lack of in vivo AD models (Beach et al., 2000; Boncristiano et al., 2002).  On the other 
hand, it should be noted that sevral studies have reported contrasting results showing a 
decrease or no changes in the APP levels after lesion of the cholinergic basal forebrain 
(Ramirez et al., 2001; Apelt et al. 1997; Rossner et al., 1997).  
Together, these findings imply a role of cholinergic dysfunction in the 
promotion of Aβ production, and, further, support the notion that treatment with ChEIs 
may slow down the disease progression by modulating APP processing into the less 
amyloidogenic direction (Giacobini, 2001).   
2.3.4. Hippocampus, septohippocampal cholinergic pathway, and fimbria-fornix 
lesion 
One of the main outputs of the basal forebrain cholinergic system of rats is 
through the septohippocampal pathway, i.e. the projection from the medial septal 
nucleus and diagonal band of Broca to the hippocampal formation, the other main 
output are the projections to the neocortex.  
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We use the term hippocampal formation to encompass three subregions: the 
dentate gyrus, hippocampus proper, and subiculum (Amaral and Witter, 1995; Amaral 
and Witter, 1989).  Typically, in the rat the hippocampus proper is subdivided into three 
subregions, i.e. CA1, CA2, and CA3 (Figure 3).  The main population of neurons 
consists of a dense, thin layer of large pyramidal cells, which form stratum pyramidale 
(sp), the layer above stratum pyramidale is stratum oriens (so), the layer immediately 
below stratum pyramidale is stratum radiatum (sr), and the layer near the fissure is 
called the stratum lacunosum-moleculare (slm).  The dentate gyrus is subdivided in a 
molecular layer (stratum moleculare, sm), the granule cell layer and a polymorphic cell 
layer (Figure 3).  The subiculum has three principal layers, i.e. the molecular layer, an 
enlarged pyramidal cell layer containing the soma of the principal neurons, and a deep 
polymorphic layer (not illustrated).  The principal cell layer of the subiculum is mainly 
populated with large pyramidal neurons; among these are many smaller neurons, which 
are considered the interneurons of the subiculum (O’Mara et al., 2001). 
 
Figure 3.  A photomicrograph of a Nissl stained coronal section through 
 the dorsal hippocampus of the mouse shows the anatomy and the 
 laminar organization of the hippocampus.  
 
  The septal complex is divided into two parts: the medial septum/diagonal band 
of Broca (MS/DB) complex and the lateral septum (LS) (Figure 4).  The MS/DB 
complex is divided into medial septal nucleus (MS) and nucleus of the diagonal band of 
Broca (DB).  The DB is composed of two parts: the vertical limb of DB (VDB) and the 
horizontal limb of DB (HDB).  The cholinergic innervation of the hippocampus mainly 
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originates from the MS and the HDB and VDB, and reaches the hippocampal formation 
via three anatomically distinct routes (Cassel et al., 1997), i.e. the cingulum bundle, the 
fimbria-fornix, and a ventral pathway (Figure 4).  The fimbria-fornix pathway carries 
the largest part of cholinergic afferents to the hippocampal formation (approximately 
75%), and the supracallosal and ventral pathways contribute a smaller part of the 
cholinergic innervation (Storm-Mathisen and Guldberg, 1974).  In addition, the fimbria-
fornix pathway carries a GABAergic projection from the MS/DB to the hippocampus 
(Kohler et al., 1984), a monoaminergic projection to the hippocampus from the 
brainstem (Gage et al., 1983a and 1983b), and the descending projections from the 
hippocampal formation to the septum (i.e. the hippocamposeptal pathway) (Toth et al., 
1993); therefore, a fimbria-fornix transection is not entirely cholinergic-specific as it 
also lesions above pathways. 
 
Figure 4.  Schematic diagram of a sagittal view of the rat brain showing 
the main pathways of the septal nuclei innervation of the hippocampal 
formation.  The fibers arising in the medial septal nucleus (MS) and 
vertical limb of the diagonal band of Broca (VDB) reach the 
hippocampal formation via the fimbria (fi), and the dorsal fornix (df), 
and the cingulum bundle (overlying the corpus callosum, cc).  The 
ventral pathway to the hippocampal formation mainly originates from the 
nuclei of the diagonal band of Broca (i.e. both VDB and HDB).  
Abbreviations: VDB and HDB, nuclei of the vertical and horizontal 
diagonal band of Broca, respectively; HipD and HipV, dorsal and ventral 
portions of the hippocampus, respectively (modified from a figure by 
Gaykema et al, 1990). 
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Fimbria-fornix lesions had been used as an experimental animal model of AD in 
order to test potential therapeutical interventions.  Fimbria-fornix lesion can be made by 
aspiration or transection, and this will result in a dramatic depletion of cholinergic 
markers in the hippocampus (Henderson, 1996).  AChE staining disappears completely 
in the dorsal hippocampus after a transection of the fimbria-fornix, but the cholinergic 
innervation in the ventral hippocampus is partially retained because it receives part of 
its cholinergic input from the MS/DB via a ventral route (Gage et al., 1984; Gaykema et 
al., 1990) (Figure 4).  Rats with a fimbria-fornix lesion have been shown to be 
significantly impaired in spatial learning and memory tasks, including the radial arm 
maze task and the Morris water maze (reviewed by Cassel et al., 1997).  
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3. AIMS OF THE STUDY  
 
The deposition of amyloid-β peptides (Αβ) and neurofibrillary tangles are the 
two characteristic pathological features of Alzheimer’s disease (AD), but cholinergic 
dysfunction is also a common feature of the disease.  Both in vitro and in vivo studies 
have suggested that cholinergic neurotransmission may be involved in the regulation of 
APP processing. However, the role of altered levels of acetylcholine (ACh) in the 
regulation of APP metabolism and Aβ production has not yet been investigated in an in 
vivo model of AD. 
The primary aim of our study was to examine the role of acetylcholine (ACh) 
levels in the regulation of APP metabolism and/or Aβ production in the 
APPswe+PS1(A246E) transgenic mouse model of AD.  The second aim was to study 
the relation between Aβ overproduction and/or deposition, and the cognitive decline in 
these mice.   
The specific aims of this study were: 
 – To study whether an increase in the level of ACh, induced by chronic treatment 
with a ChEI, would affect APP processing and decrease Aβ production, and thus slow 
down amyloid deposition in AP mice (I). 
 – To elucidate whether a decrease in the level of ACh, produced by fimbria-fornix 
transection, could induce APP production and increase Aβ levels in the brain, and thus 
accelerate amyloid deposition in AP mice (II). 
 –  To behaviourally characterize the cognitive deficits in AP mice and study its 
potential relationship with amyloid deposition in the hippocampal formation (III). 
 –  To investigate whether the levels of Αβ in the different compartments of the 
CNS and periphery correlate with impaired spatial learning and memory in AP mice 
(IV). 
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4. MATERIALS AND METHODS  
4.1. Animals 
Male APPswe and PS1(A246E) double transgenic mice (AP mice) and 
nontransgenic littermate controls (NT mice), aged from 4.5 months to 14 months, were 
used in the present study [study I: AP, n = 56, NT, n = 56; study II: AP mice, n = 124, 
NT mice, n = 116; study III: AP mice, n=100; NT mice, n=145; study IV: AP, n=37, 
NT, n=34).  They were generated from matings between APPswe transgenic mice and 
PS1(A246E) transgenic mice.  The fouder mice, i.e. APPswe Tg-mice expressing a 
chimeric mouse/human (mo/hu) APP695 harboring a human Aβ domain and mutations 
(K595N and M596L) linked to FAD (i.e. Swedish mutations), and PS1(A246E) Tg-
mice expressing a mutated human PS1(A246E), were originally generated by Dr. 
Borchelt (1997) at Johns Hopkins University (Baltimore, MD, USA), and they are now 
bred locally on a C57BL/6J background. Throughout the period of the experiments the 
animals were housed individually in a controlled environment (temperature 22ºC, 
humidity 50-60%, light schedule from 0700-1900).  Food and water were available ad 
libitum, except during the radial arm maze and the delayed alternation and position 
discrimination tasks in the T-maze testing period.  During these tests the mice were kept 
on food restriction to limit their weights to 80-85% of the free-feeding weight, and the 
body weights were checked daily before the behavioural testing.  The experiments were 
conducted according to the Council of Europe (Directive 86/609) and Finnish 
guidelines, and approved by the State Provincial office of Eastern Finland. 
4.2. Drug treatment 
Metrifonate (MTF, a donation from Bayer, Leverkusen, Germany) was freshly 
dissolved in 5% sodium citrate buffer (pH 5.5) on each experimental day.  MTF (100 
mg/kg/day) was given p.o. five days per week and continued for 7 months.  The choice 
of this dose was based on a preliminary dose response study (unpublished findings) in 
which five groups of single PS1 mutant transgenic mice (n = 9 mice/group) were treated 
(p.o.) with MTF (5 days/week) for 6 weeks at doses of 0, 25, 50, 100 and 150 mg/kg.  
The dose of 100 mg/kg yielded the maximum inhibition of AChE activity, i.e. 81%.  In 
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clinical trials, this level of AChE inhibition (but not 66% or less) has been shown to 
induce cognitive improvements in AD patients (Pettigrew et al., 1998).  
4.3. Surgery procedures 
4.3.1. Fimbria-fornix lesion 
The lesion method was adapted from the method of Goss and Morgan (1995).  
In short, under general anesthesia (pentobarbital + chloralhydrate [50/50]; 36 mg/kg, 
i.p.) the mouse was placed in a stereotactic frame, and the skull was exposed.  A 1.6 mm 
slot was drilled through the skull between 0.8 mm and 2.4 mm lateral, and 0.1 mm 
posterior to Bregma, according to mouse brain atlas (Franklin and Paxinos, 1996).  In 
order to completely cut the fimbria-fornix, two cuts were made from the same starting 
point (0.8 mm lateral and 0.1 mm posterior to Bregma).  For the first cut, a 1 mm-wide 
knife blade was lowered 3.5 mm from the surface of the brain through the slot at a 26o 
angle and moved 1.6 mm laterally.  The second cut was made as the knife was lowered 
3.3 mm vertically and moved 1.0 mm laterally.  Sham-operated animals underwent the 
same surgical procedure but without the knife insertion. 
4.3.2. Cisterna magna puncture for cerebrospinal fluid (CSF) 
CSF samples were taken from the cisterna magna according to a method that 
was adapted from the method of Meyding-Lamade et al (Meyding-Lamade et al., 1996).  
In short, the mice were anesthesized and placed prone on the stereotaxic instrument. A 
sagittal incision of the skin was made inferior to the occiput.  Blunt separation of the 
subcutaneous tissue and neck muscles through the midline was performed without 
detachment from the skull under a dissection microscope.  A microretractor was used to 
hold the muscles apart.  Then the mouse was laid down such that a nearly 135 o between 
the body and the head was present.  Under this angle the dura and spinal medulla are 
visible, they have a characteristic glistening and clear appearance, and the circulatory 
pulsation of the medulla and adjacent CSF space can be seen.  The dura was then 
penetrated by a glass capillary, which was 6 cm long, and had a diameter of 1 mm. 
Following a noticeable change in resistance to the capillary insertion, the CSF flowed 
into the capillary.  The average volume of CSF obtained was approximately 7 µl. 
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4.4. Behavioural testing  
 4.4.1. Water maze task 
The Morris water maze (WM) has been developed to measure spatial learning 
and memory in the rat, and it has been shown to be particularly sensitive to the effects 
of hippocampal lesions (Morris et al., 1982; reviewed by D'Hooge and De Deyn, 2001).  
The apparatus was a black plastic pool with a diameter of 120 cm, and with 25 cm high 
walls.  A black escape platform (square, 10 cm x 10 cm) was used, either 0.5 cm above 
(visible) or 1.0 cm below (hidden) the water surface.  The water was kept at a constant 
temperature throughout the experiments (20.0 ± 1.0°C). (Figure 5) 
First, the mice were pretrained to find and climb onto the submerged platform 
for two days by using an alley with high black walls leading to a large platform (14 x 14 
cm).  Mice were allowed to swim until they found the platform or for a maximum of 20 
s before they were placed on the platform for 10 s.  This procedure was repeated 8 times 
consecutively on each pre-training day. 
During testing days 1-5, mice were trained to find a hidden platform that was 
constantly kept in the middle of the southwest quadrant throughout these 5 days (spatial 
version of WM task), and each mouse performed 5 trials/day.  The mice were placed in 
the water facing the wall to begin the first daily trial from the starting point farthest 
from the platform (i.e. East or North); the other 4 trials were started in a semi-random 
starting point order.  The latency to find the submerged platform was timed manually by 
the experimenter.  A video camera was connected to an image analyzer (HVS Image, 
Hampton, UK), and a microcomputer was used to record the swim path.  The mice were 
given 50 s to find the platform, and then were allowed to stay on the platform for 10 s.  
If the mouse failed to find the escape platform in the maximum time (50 s), the 
experimenter would gently place it there for 10 s.  Mice were tested in groups of four 
with each mouse having one trial in turn, so that the intertrial interval was 
approximately 5 min.  For Study IV, on the sixth day the platform was removed from the 
pool and the mouse was allowed to swim for 50 s as a probe trial for its search bias. 
During testing days 6-7 (for Study I and III), a black curtain was hung around 
the swimming pool in order to conceal the extramaze visual cues.  The mice were 
trained to find a visible platform (cued version of WM task), which had a 10 cm high 
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pole with a white flag and which was changed every trial to a novel position.  Daily 
sessions were the same as in the hidden platform version.  During the water maze 
training, swimming speed, latency to find the platform, escape length and the 
percentage of trials that each animal found the platform were measured. 
 
 
PlatformHidden Platform
West
North South
c. d.
East
b.
Visual Cuesa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  A schematic illustration of the Morris water maze test (spatial 
navigation version). (a). The water maze pool, an escape platform was 
placed in the southwest quadrant just below the surface of the water.  
Mice were trained to learn the position of the hidden platform by using 
the external visual cues around the maze.  They were released into the 
water from one of four starting points (North, East, South, West.  (b-d) 
Examples of swimming paths of a control mouse during the water maze 
training.  (b) At the beginning, the mouse was randomly searching for the 
platform, and it found the platform only by chance.  (c). After learning 
the position of the hidden platform, the mouse swam directly to the 
platform. (d). During the probe trial, the mouse mainly searched around 
the former location of the platform. 
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4.4.2. Radial arm maze tasks 
The radial-arm maze (RAM) can be used to measure both long-term reference 
memory and short-term working memory (either spatial or nonspatial).  This study used 
a design similar to the one developed by Olton et al. (1978) for rats and adapted to the 
mouse by Crusio et al. (1987).  The 8 arms radiate out from an octagonal plexiglas 
center, 22 cm in diameter.  The plexiglas arms were 25 cm long, 6 cm wide, and 6 cm 
high.  The entrance to the arms can be blocked by removable guillotine doors.  Rice 
crispies (Kellogg’s) were placed at an inaccessible recess at the end of each arm behind 
a perforated wall to give all arms a uniform scent.  Two versions of RAM task were 
employed in this study. 
4.4.2.1. Win-shift task in the radial arm maze 
Acquisition  
The win-shift version of RAM task can be used to measure spatial learning and 
memory, which is sensitive to hippocampal lesion (Olton et al., 1978).  Mice were 
trained to collect food rewards from every arm of the radial maze (see Figure 6-a).  
Prior to the experiment, mice were handled for 2 min daily for 4 days.  A food 
restriction schedule was initiated simultaneously with handling.  The body weight of 
mice was thus progressively reduced and subsequently maintained at 80-85% of the free 
feeding level throughout testing.  The mice were first familiarized to the RAM by 
letting them explore it freely with all arms open for 10 min on two days, during which 
time food reward was available at the end of each arm.  During the experimental phase, 
all the eight arms were baited. A single food reward (rice crispies, Kellogg’s) was 
placed immediately in front of the perforated wall, but behind a low visual barrier (1 
cm).  Each trial began with the placement of the mice on the central platform, with all 
doors closed.  After 5 s, all doors were opened.  An entry was defined as all four paws 
entering the arm, and an entry into an arm from which it had already retrieved the food 
pellet was deemed an error.  The mice were removed from the RAM after retrieval of all 
rewards, or after a total of 16 arm entries had been made or after 10 min had passed, 
whichever came first.  After each return to the center from an arm, the doors were 
closed for 5 s.  This discouraged the mouse from utilizing mediating strategies.  Because 
of large inter-individual variability in the number of errors before finding the most 
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difficult 8th reward, the performance was evaluated on the basis of total number of 
errors made before the 7th correct choice.  Learning of the RAM took 15 days, which 
were averaged into 5 blocks of 3 days in the analysis. 
Retention 
After a two-week interval, the mice were again tested in the RAM for two days.  
Thereafter, the same procedure was repeated every month until the end of the testing 
period (i.e. three months later). 
 
a. b.
Figure 6.  Schematic illustration of the two versions of the radial arm 
maze (RAM) test.  (a). The win-shift version of RAM.  All eight arms 
were baited with food rewards. The mouse had to visit each arm once in 
order to most efficiently find the food rewards.  (b) The win-stay version 
of RAM.  Only one arm was constantly baited with food reward.  After 
repeated training, a mouse learnt to only visit the baited arm and ignore 
the unbaited arms. 
 
4.4.2.2. Win-stay task in the radial arm maze  
The win-stay version of RAM is a nonspatial learning and memory task (adapted 
from the method of Jarrard, 1978).  In this task, one randomly selected arm was 
constantly baited throughout the 5 days of testing.  The mice were trained to enter the 
one baited arm and to avoid the remaining seven non-baited arms (see Figure 6-b).  
Each trial began with the placement of the mice on the central platform with all doors 
closed.  After 5 s, all doors were opened.  Each trial was completed when the mouse 
reached the end of the baited arm and returned to the central platform after consuming 
the food reward.  The doors, which were kept open during the trial, were then closed.  A 
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30 s intertrial interval was used.  The mice were given 8 daily trials and trained for five 
days.  The total number of errors was recorded for each testing day.  
4.4.3. T-maze Tasks 
4.4.3.1. Delayed alternation in the T-maze 
The delayed alternation task in the T-maze was used to measure working 
memory (Tanila et al., 1999), which is dependent on the functional integrity of the 
septo-hippocampal system (Brito et al., 1983; Murray and Fibiger, 1986).  
Apparatus 
The T-maze consists of a stem (38 x 7 cm) and two arms (35 x 7 cm).  A sliding 
door separated the first 11 cm of the stem as the starting compartment, and a door at 
each arm separated the arm from the stem 8.5 cm from the intersection.  The walls were 
painted black and were 14 cm high to encourage the use of an egocentric response 
strategy.  The source of illumination was an incandescent light located above the stem 
of the maze.  
Pretraining 
After four days of food restriction, the mice were familiarized with the maze by 
giving them a 10-min period of free exploration with about 10 rewards scattered on the 
floor of the maze.  Each mouse was given repetitive daily sessions of 10 min until it ate 
most of the rice rewards during the session. 
Training session 
The mice were trained to visit one arm, eat the food reward, and return to the 
starting compartment.  If the mouse did not leave the starting compartment in 5 s after 
the door was opened, the experimenter would gently push the mouse.  After two visits 
into the same arm, that arm was blocked with the slide door forcing the mouse to visit 
the opposite arm.  When the mouse spontaneously chose each arm successively, the 
actual alternation training began with 15 trials daily.  On the first trial both arms were 
baited.  After the mouse had chosen one arm and eaten the food reward, it was returned 
to the start compartment and confined there for 10 s.  On the following trials the food 
reward was located in the arm that was not visited on the previous trial.  After the 
mouse had entered one arm, it was confined there by a slide door for 20 s.   Thereafter it 
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was given 10 s to return to the staring compartment, while the access to the opposite 
arm was blocked by a door.  The baited arm remained the same until it was visited even 
if the mouse repeatedly visited the incorrect arm.  The training was continued until the 
mouse make 11 or more correct choices of 15 trials in three consecutive days.  If a 
mouse failed to reach the criterion by the end of 10 days, it was dropped for the mixed-
delay testing session (Figure 7-a, -b and -c). 
Mixed-delay testing sessions 
The delayed alternation test session consists of 15 trials in which three delays 
(20, 60, 100 s) were varied in a pseudorandom order that was the same for all animals in 
a given session.  This test phase took three days.  The procedure was the same as in the 
training phase except for the delays.  Choice accuracy was evaluated by counting the 
total number of errors. 
4.4.3.2. Spontaneous alternation in the T-maze 
Based on the animal’s natural tendency to explore novelty, the spontaneous 
alternation in the T-maze task was designed to assess exploratory behaviour and 
working memory in an unbiased way (Gerlai, 1998).  The apparatus consisted of a start 
stem and two goal arms (length of start and goal stems=75 cm, width=12 cm, height=20 
cm).  The walls of the maze were made of transparent acrylic and were glued to a matte 
black acrylic square bottom piece.  The maze was equipped with three removable 
sliding doors.  One separated a 24-cm compartment at the beginning of the start arm, 
and the other two were placed at the entrance of each goal arm and could be lowered to 
block entry.  The procedure consisted of one forced and 14 choice trials.  On the first 
trial, the mouse was allowed to explore the start arm and one of the goal arms of the 
maze.  The entry was blocked to the other goal, which was chosen in a semi-random 
order.  When the mouse left the explored goal arm and re-entered the start arm, it was 
confined there for 5 s by lowering the slide door.  On the second trial, the door of the 
previously blocked arm was lifted and both goal arms were open to the mouse.  After 
the mouse had chosen and entered one goal arm, the opposite goal arm was blocked by 
the door.  The mice left the explored goal arm and eventually went back to the start arm 
again.  It was confined there for 5 s and the testing circle started again with another free 
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choice trial.  Consecutive choices made by the mouse were recorded and the total 
alternation rate during the 14 free choice trials was calculated. 
 
 
 
Figure 7.  Schematic illustration of the two food-motivated learning and 
memory tasks in the T-maze.  (a), (b), and (c) show the testing procedure 
of the delayed alternation task in the T-maze.  In the first free trial, the 
mouse was allowed to make either a left or a right turn to retrieve the 
food reward (a). During the following trials, the mouse must make 
consecutive alternations in order to obtain the food rewards (b, c). Thus 
the correct choices are based on remembering the previous visits (i.e. 
working memory).  (d), (e) and (f) show the testing procedure of the 
position discrimination task in the T-maze.  The baited arm was selected 
during the first free trial, which was opposite to the mouse’s preference 
(d).  For the following trials, this arm was constantly baited (e, f). The 
performance in this task is largely based on habituation learning. 
 
4.4.3.3. Position discrimination in the T-maze 
The position discrimination task in the T-maze was used to measure egocentric 
memory.  The apparatus was the same as that was used in the delayed alternation task.  
Food restriction was introduced in order to reduce the weights of mice to 80-85% of 
their normal body weight.  Mice were handled and weighed daily, and they were 
familiarized to the T-maze by letting them freely explore it for 10 min until they 
repeatedly ate the rewards at both arms of the maze.  On the initial trial of the first 
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testing day, both arms of the maze were rewarded to test the spontaneous turning 
preference of the animal.  After this trial, the arm that the mouse did not select was 
baited for for all three days (or four days, Study I) of testing.  Each mouse was given 15 
consecutive trials per day.  A 1-min intertrial interval was introduced between the trials 
during which time the animal was confined to the starting compartment. For Study I, on 
the fifth day, the location of the food reward was changed to the other arm, and this arm 
remained rewarded for three days. The total number of errors over the 15 trials was 
recorded daily (Figure 7-d, -e, -f). 
4.4.4. Other paradigms 
Two additional tasks were run to detect possible alterations in motor function, 
exploratory behaviour and emotional behaviour (e.g. anxiety or fear) due to drug 
treatment, brain lesion or transgenic manipulation.   
4.4.4.1. Open field  
The open field test was used to assess both exploratory behaviour and locomotor 
activity.  All mice were tested using automated TruScan system with infrared 
photodetectors (Coulbourn Co, USA).  The system consists of four identical 26 x 26 x 
39 cm plexiglas cages, an interface station and a microcomputer for data recording and 
analysis.  Two photobeam sensor rings were employed to detect the animal’s movement 
in two planes.  Horizontal activity (XY-move time), vertical activity (rearing), center 
move time and stereotypic move time were measured for 10 min in the first testing day 
and repeated after 48 hours for another 10 min. 
4.4.4.2. Elevated plus-maze 
The elevated plus-maze was used to measure the anxiety level of the mice 
(Lister, 1987).  The apparatus was made of black plastic, and consisted of two opposite, 
open arms (length 30 cm, width 5 cm, ledge 0.25 cm) and two opposite, enclosed arms 
(30 cm x 5 cm x 15cm).  The arms were connected by a central platform (5 x 5cm), 
together forming a plus shape. The maze was elevated 40 cm from the floor, and it was 
illuminated by a 40-Watt light bulb.  Each mouse was placed on the central platform 
facing an open arm and allowed to freely explore the maze for 5 min.  At the end of 
each trial, the maze was thoroughly cleaned with a damp cloth.  The time spent on the 
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open and enclosed arms was recorded semi-manually with a computer program.  The 
percentage time spent on the open arms [open time/ (open + close time) x 100] was 
calculated.  An increase in the percentage of time spent on the open arms is interpreted 
as an anxiolytic response, whereas a decrease indicates a higher level of anxiety. 
4.5. Biochemical assays 
4.5.1. APP Western-blot 
The dissected hippocampi were homogenized in phosphate buffered saline (PBS, 
pH 7.2) containing 1 mM Complete protease inhibitor (Boehringer Mannheim).  After 
centrifugation the supernatants were collected, and the remaining pellets were 
homogenized in 1% Triton X-100-PBS containing Complete, and centrifuged.  
Protein samples (30 µg) were subjected to 7.5% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis and transferred to a nitrocellulose filter.  Monoclonal anti-APP IgG 
(clone 22C11, Boehringer Mannheim), which detects both human and mouse APP, was 
used as primary antibody and alkaline phosphatase conjugated anti-mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc.) as secondary antibody.  APP immunoreactivity (in 
optical density units, OD) was visualized using ECF substrate for Western blotting 
(Amersham Pharmacia Biotech) and STORM-fluoroimager (650 mV, 200 microns, 
Molecular Dynamics). 
 4.5.2. Αβ ELISA 
The hippocampi were weighed and homogenized in phosphate buffered saline, 
pH 7.2, containing a mixture of protease inhibitors (CompleteTM, Boehringer 
Mannheim, Germany).  After centrifugation at 218,000g for 2 h at 4° C the supernatants 
containing soluble Αβ42 were collected.  The remaining pellets containing insoluble Aβ 
were homogenized in guanidine buffer (5.0 M guanidine-HCl/50 mM Tris-HCl, pH 
8.0), incubated 3 hours at room temperature, centrifuged, and diluted to reduce the 
concentration of guanidine-HCl to 0.5 M (Johnson-Wood et al., 1997).  All samples 
were stored at – 70° C until the analysis. 
The samples, and the Aβ peptides that were used as standards, were prepared to 
contain 0.5 M guanidine-0.5% BSA-1 mM AEBSF in the final composition.  The levels 
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of Αβ42 in CSF and soluble Αβ42 in the hippocampi were quantified using the Innotest 
β-amyloid1-42 High Sensitivity Test–ELISA kit (Innogenetics, Belgium), and the levels 
of Αβ40 in serum and insoluble Αβ40 and Αβ42 in the hippocampi were quantified 
using the Signal Select Beta Amyloid ELISA Kits (BioSource International Inc.).  
Both kits use antibodies that do not recognize mouse endogenous Αβ (Innogenetics, 
Johnson-Wood et al., 1997; BioSource, manufacturer’s report).  The Αβ42 and Αβ40 
levels in hippocampi were standardized to brain tissue weight and expressed as ng (Αβ) 
/ g (brain tissue), and the levels of Αβ42 in CSF and Αβ 40 in serum were expressed as 
pg/ml. 
4.5.3. ChAT activity 
Hippocampal and cortical tissues were homogenized in buffered (50µM sodium 
phosphate buffer, pH 7.4) 0.32 M sucrose (10v/w) using a Potter-Elvehjem 
homogenizer (1000 rpm, six strokes) in an ice bath. ChAT activity was measured in 
duplicates according to the method of Fonnum (1975). 
4.6. Histology 
Histology 
Mice were anesthetized, and transcardially perfused with 0.9 % saline followed 
by 4% paraformaldehyde in 0.1 M Na-phosphate buffer (pH 7.4).  The brains were 
removed and placed in the fixative for 2 hours, then transferred to a 30% sucrose 
solution, in which they were kept overnight on a shaker table.  Following this procedure 
the brains were either cut, or stored in antifreeze. Six series of coronal sections (35 µm, 
1 in 6 series) were cut through the brain using a sliding, freezing microtome.  The first 
series of sections was stained with cresyl violet for general morphology, the second 
series was silver-stained to analyze amyloid plaques (Garvey et al., 1991), the third 
series was histochemically stained for AChE to visualize cholinergic fibers (van Groen 
and Wyss, 1992).  The fourth series was immunohistochemically stained for Αβ using 
the W0-2 antibody, which was raised against the 1-16 amino acid sequence of human 
Aβ (Jensen et al., 2000).  The other two series were stored in antifreeze in freezer for 
future use.  For the W0-2 staining, the sections were rinsed overnight in Tris-buffered 
saline (TBS), and then the series of sections was transferred to a solution containing the 
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primary antibody (mouse anti-human Αβ, 1:20000, W0-2; this solution consists of TBS 
with 0.5 % Triton X-100 added [TBS-T]).  Following incubation in this solution for 18 
h on a shaker table at room temperature (20oC) in the dark, the sections were rinsed 
three times in TBS-T and transferred to the solution containing the secondary antibody 
(goat anti-mouse*biotin; Sigma).  After two hours, the sections were rinsed three times 
with TBS-T and transferred to a solution containing mouse ExtrAvidin® (Sigma) for 2 
hours.  Following rinsing the sections were incubated for approximately 3 min with Ni-
enhanced DAB (10 mg DAB in 20 ml 0.1 M phosphate buffer, 30 µl H2O2 [30%], pH 
7.4 with 1 ml of a 15% ammonium Ni-sulfate solution added).  All stained sections 
were mounted on slides and coverslipped. 
Measurements 
The number of amyloid plaques in the dorsal hippocampal formation (i.e. in 
CA1, dentate gyrus and subiculum) was counted using the silver-stained material for AP 
mice (I, II).  Three sections (or seven, Study I) through the hippocampus beginning at 
approximately 200 µm posterior to bregma were used for counting plaque number. 
Similarly four sections (or seven, Study I) beginning at approximately 540 µm posterior 
to bregma were used for counting the plaque numbers in dorsal subiculum.  The 
sections were digitized using a Nikon Coolpix 990 digital camera, and the images were 
converted to gray scale using the Adobe Photoshop 5.5 program.  The size of each area 
of the hippocampal formation was measured using the Scion Image (NIH) program.  
The plaque counts were calculated per unit brain area and these values were normalized 
with reference to the dorsal subiculum.  From the adjacent, W0-2 stained sections, the 
Αβ load in the hippocampal formation was measured.  In short, the appropriate areas of 
the sections were digitized by the same procedure described above.  The percentage of 
area covered by the reaction product to Αβ in CA1, dentate gyrus and dorsal subiculum 
was measured using the Scion Image (NIH) program. 
4.7. Experimental design 
Study I 
Seven-month-old male APPswe and PS1(A246E) doubly transgenic mice (AP 
mice, n = 56) and nontransgenic littermate controls (NT mice, n = 56) were used in this 
study.  Both AP and NT mice were randomly assigned to either MTF or vehicle groups 
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(n = 28 mice / group).  Drug (100 mg/kg/day) or vehicle was given p.o. five days per 
week and continued for 7 months.  The behavioural tests (open field, water maze, the 
position discrimination task in the T-maze) were conducted after 6 months treatment 
with MTF.  At the end of the testing period, eight mice of each group were 
transcardially perfused for histopathology; the other 20 mice were sacrificed, and the 
hippocampi and cortices were dissected for measurement of ChAT activity and levels of 
APP, Αβ40 and Αβ42. 
Study II 
Male AP mice (n = 124) and non-transgenic littermate controls (NT mice, n = 
116) were used in this study. 
One short, preliminary experiment, and two long-term experiments were 
performed. 
Preliminary Experiment    
Thirty-nine AP mice and 32 NT mice were FFX lesioned or sham-operated at 
the age of 4.5 months (AP-FFX, n=19; AP-sham, n=20; NT-FFX, n=16; NT-sham, 
n=16).  Following a two weeks recovery period, the mice were sacrificed and the 
hippocampi were dissected for measurement of ChAT activity and the levels of APP, 
Αβ40 and Αβ42. 
Experiment 1      
Forty-eight AP mice and 48 NT mice were FFX lesioned or sham-operated at 
the age of 5 months (AP-FFX, n=24; AP-sham, n=24; NT-FFX, n=24; NT-sham, n=24).  
Three months later (at 8 months of age), eight mice of each group were transcardially 
perfused for histopathology; the other 16 mice were sacrificed, and the hippocampi 
were dissected for measurement of ChAT activity and levels of APP, Αβ40 and Αβ42. 
Experiment 2       
Forty-one AP mice and 40 NT mice were FFX lesioned or sham-operated at the 
age of 7 months (AP-FFX, n=21; AP-sham, n=20; NT-FFX, n=20; NT-sham, n=20).  
After 11 months (at 18 months of age), eight mice of each group were transcardially 
perfused for histopathology; the other mice were sacrificed and the hippocampi were 
dissected for measurement of ChAT activity and Αβ 40 and Αβ42 levels. 
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Study III 
Male AP mice (n = 100) and NT mice (n = 145) were used in this study.  In total 
127 mice (AP mice, n=40; NT mice, n=87) were randomly assigned to fimbria-fornix 
lesion (FFX-lesion) or sham-operated groups (all mice of experiment 2, study II were 
included.).  Four experiments were performed: Experiments 1 and 2 consisted of a large 
battery of behavioural tasks that have earlier been reported to be sensitive to FFX lesion 
in rats or mice, in contrast, experiments 3 and 4 consisted of behavioural tasks in which 
hippocampal or FFX lesions have not been shown to result in impaired performance.  
Experiment 1 
Twenty-four AP and 24 NT mice received a FFX lesion or were sham operated 
at the age of 7 months (AP-FFX, AP-sham, NT-FFX, NT-sham, n = 12/group).  After 7 
months recovery the mice were tested in the win-shift task in the radial arm maze, 
elevated plus-maze, and spontaneous alternation task in the T-maze.  
Experiment 2 
Sixteen AP mice and 17 NT mice received a FFX lesion or were sham operated 
at the age of 7 months (AP-FFX, AP-sham, NT-FFX, NT-sham, n = 8-9/group).  Ten 
months after the lesion, the mice were tested delayed alternation task in the T-maze and 
water maze.  
Experiment 3 
Separate groups of NT mice were FFX-lesioned (NT-FFX, n=24) or were sham 
operated (NT-sham, n=22) at the age of 5 months.  After a 3 months recovery period, 
the mice were tested in the win-stay task in the radial arm maze and the position 
discrimination task in the T-maze. 
Experiment 4 
Separate groups of AP and NT mice (AP, n=25; NT, n=25) were tested at the age 
of 14 months in the win-stay task in the RAM.  Another separate group of AP and NT 
mice (AP, n=17; NT, n=17) was tested at the age of 11 months in the position 
discrimination task in the T-maze.  
Study IV 
Fourteen-month-old male AP mice (AP, n=37) and nontransgenic littermate 
controls (NT mice, n=34) were used in this study.  Following the completion of the 
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water maze task, the mice (AP mice, n=22; NT mice, n=22) were deeply anesthetized, 
and CSF and blood samples were taken from the cisterna magna, and left cardiac 
ventricle, respectively.  Thereafter the mice were sacrificed, and the hippocampi were 
dissected.  The levels of soluble and/or insoluble Αβ40 and Αβ42 in brain, CSF and 
serum were measured by ELISA (AP, n=22; NT=4). 
 4.8. Statistical analyses 
All statistical analyses were carried out using SPSS for Windows software 
(version 8.0, SPSS Inc., USA).  The effects of mouse genotype, drug treatment or 
lesion, training day or trials, and their interactions on locomotor activity and maze 
performance of mice were analyzed by univariate analysis of variance (ANOVA) or 
ANOVA for repeated measures.  The effects of genotype and drug treatment or lesion 
upon APP level, Aβ levels, ChAT activity, density of AChE positive fibers, amyloid 
plaque counts, amyloid plaque density, Αβ load and hippocampal CA1 width were 
analyzed with ANOVA or independent-samples t- test.  The correlations among Aβ 
levels in CSF, serum, brain and water maze learning were analysed with Pearson’s 
correlation analysis. 
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5. RESULTS  
5.1. Effects of metrifonate on cholinergic activity, amyloid pathology, and cognitive 
function in AP mice (I) 
5.1.1. Changes in cholinergic activity 
No genotype-related difference was found in the density of AChE positive fibers 
in the hippocampus or in the parietal cortex.  In both genotypes, and brain areas, MTF 
treatment continued to inhibit AChE highly significantly.  The average AChE activity in 
the MTF treated animals was 54.7 ± 2.6 % (mean ± SEM) in the hippocampus and 61.0 
± 5.0 % in the parietal cortex relative to that of vehicle treated animals (I, Figure 4 and 
5A).  However, the degree of AChE inhibition after 7 months of chronic MTF 
administration is considerably less than the 81% inhibition after 5 weeks of treatment.  
No genotype or treatment main effect was found for the ChAT activity in the 
hippocampus or parietal cortex; however, the ANOVA revealed a significant genotype x 
treatment interaction for the ChAT activity in the parietal cortex.  The ChAT activity in 
the parietal cortex was slightly higher in untreated AP mice (1.05 ± 0.19 nmol/mg 
prot/h; mean ± SEM) than in NT mice (0.90 ± 0.17 nmol/mg prot/h) and tended to 
decrease after MTF treatment in AP mice while it was increased in NT mice (Figure 
5B).  ChAT activity in the hippocampus showed a similar, but non-significant trend. 
5.1.2. Effects on amyloid metabolism 
The hippocampal APP levels were approximately 100 % higher in AP mice than 
in NT mice at the age of 14 months.  The genotype effect was highly significant but no 
treatment effect or genotype x treatment interaction on APP levels was found.  
Hippocampal Aβ40 and Aβ42 could not be detected in NT mice but reached high levels 
(compared to 5 and 8 month old AP mice, II) in the 14-month-old AP mice. The levels 
of Aβ42 were about three times higher than those of Aβ40.  The treatment effect was 
highly significant for both Aβ40 and Aβ42 levels; but contrary to the hypothesis, the 
levels were higher in the MTF treated group (I, Figure 2).  On the other hand, the Aβ42 
to Aβ 40 ratio significantly decreased from 4.3 ± 0.4 (mean ± SEM) of the vehicle 
treated AP mice to 3.2 ± 0.3 in the MTF treated AP mice.  
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Amyloid plaques were most frequently detected in the dorsal hippocampal 
formation (hippocampus proper and subiculum; I, Figure 3).  Table 1 of (I) summarizes 
the total plaque counts in 7 sections of the dorsal hippocampal formation in 8 vehicle-
treated and 8 MTF-treated AP mice.  The number of plaques did not differ between the 
treatments.  
The width of the hippocampal CA1 area in the four groups of mice is also 
summarized in Table 1 of (I).  No difference between the groups was detected indicating 
that amyloid pathology or the presence of mutated APP is not associated with shrinkage 
of the hippocampus, as has been reported in the PDAPP transgenic mice (Dodart et al., 
2000). 
5.1.3. Behavioural findings 
In the open field, the ANOVA revealed genotype and treatment main effects but 
no significant interactions.  The AP mice exhibited less horizontal locomotor activity 
and less rearing than the NT mice.  Chronic treatment with MTF decreased horizontal 
locomotor activity and rearing in both genotypes.  
In the water maze no genotype difference was observed in the swimming speed, 
but MTF treatment significantly reduced the swimming speed in both genotypes (I, 
Figure 1).  Because of the robust MTF effect on swimming speed, the water maze 
performance was evaluated based on the path length and not on the escape latency.  The 
path length over the 5 training days did not differ significantly between the genotypes or 
the treatments (I, Figure 1).  However, the analysis over the last three days, when the 
performance reached an asymptote, did reveal a significant effect of the genotype (I, 
Figure 1) but no treatment effect.  No significant interactions were observed in either 
analysis of the hidden platform task.  The AP mice were worse than NT mice in finding 
the visible platform, but no treatment effect or interaction was revealed.  However, on 
the second day of the visible platform task, the performance of the AP mice was 
comparable with that of the NT mice in both escape length and the percentage of 
platform finding. 
In the position discrimination task in the T-maze AP mice performed better than 
NT mice, both in the initial acquisition and in the reversal learning phases.  The MTF 
treatment did not affect performance of either group (Data not shown).  
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5.2. Effects of fimbria-fornix lesion on APP levels and amyloid deposition in the 
hippocampus of AP mice (II) 
5.2.1. Verification of the FFX lesion 
The preliminary experiments demonstrated that in most of the FFX mice, the 
lesions completely cut the fornix and the fimbria; however, many of these lesions 
slightly encroached on the medial part of the cingulate cortex and on the corpus 
callosum overlying the fornix.  In experiment 1, three animals had incomplete lesions, 
and the data from these animals was not included in the analysis.  In experiment 2, four 
animals showed ventricular enlargement, and the data from these animals were removed 
from the study. 
In experiment 1, three months postlesion (i.e. at eight months of age), the FFX 
transection resulted in a nearly complete loss of the hippocampal AChE positive fibers 
(II, Figure 1).  The decrease in AChE staining was higher in the hippocampus than in 
the subiculum, and, further, the decrease in AChE staining was higher in the dorsal 
compared to the ventral hippocampal formation.  In experiment 2, eleven months 
postlesion, the number of hippocampal AChE positive fibers was also significantly 
reduced, and again, similar to experiment 1, the reduction in AChE staining was more 
severe in the dorsal hippocampus than in the ventral hippocampus.  However, it should 
be noted that the reduction in AChE staining in both the dorsal and the ventral 
hippocampus was less marked 11 months postlesion (i.e. 18 months of age) than in 3 
months postlesion (II, Figure 1). 
ChAT activity in the hippocampal formation of the FFX mice was significantly 
lower than in sham-operated mice for all three age groups, and the hippocampal ChAT 
activity of AP mice did not differ from that of NT mice.  Two weeks, 3 months and 11 
months after lesion, the ChAT activity of the FFX mice was decreased by 76%, 72% 
and 52 % compared to age-matched sham-operated mice, respectively (II, Figure 2).  
The interaction between genotype and lesion was not significant for these groups. 
5.2.2.  APP and Αβ levels in the hippocampus 
The total APP levels (soluble APP [sAPP] + membrane bound APP [mAPP]) 
were analyzed only for the preliminary experiment (5-month old) and experiment 1 (8-
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month-old) mice.  The total APP level of the AP mice (which overexpress huAPP) was 
significantly higher than that of the NT mice.  There was no difference in total APP 
level between FFX mice and their sham-operated controls (II, Table 1), and the 
interaction of genotype and lesion was not significant.  In order to detect any changes in 
APP processing after cholinergic denervation (Rossner et al., 1997), the levels of sAPP 
and mAPP were analyzed separately.  In both 5- and 8-month-old groups, the sAPP and 
mAPP levels of AP mice were significantly higher than those of NT mice.  Again there 
was no difference between FFX animals and their respective controls (II, Table 1).  The 
genotype by lesion interaction was not significant between these two groups. 
The data on the Αβ levels, and Αβ42 to Αβ40 ratio are summarized in Table 2 of 
(II).  From the age of 5 months to 18 months, the Αβ40 and Αβ42 levels in the AP mice 
significantly increased.  The Αβ42 to Αβ40 ratio also increased significantly over that 
time period.  However, there were no differences between the AP-FFX and AP-sham 
mice in the Αβ40 or Αβ42 levels, nor in total Αβ levels (i.e. Aβ40 + Αβ42) at any of the 
three time points studied.  The Αβ42 to Αβ40 ratio did not differ between AP-FFX and 
AP-sham mice. 
5.2.3. Extent of amyloid deposition in the hippocampal formation 
At eight months of age, no amyloid plaques were detected in the brain of AP-
FFX mice or AP-sham mice, neither in the silver- nor in the Αβ-stained materials; and 
no amyloid pathology was present at any age in the NT mice.  Therefore only the brains 
of the 18-month-old transgenic mice of Experiment 2 were analyzed for hippocampal 
amyloid neuropathology (II, Figure 3).  In the 18-month-old AP mice, the density of 
silver stained plaques in the dentate gyrus, CA1 region and dorsal subiculum did not 
differ between AP-FFX and AP-sham mice (II, Figure 4A).  Image analysis of the Αβ 
load in the hippocampal formation demonstrated that there were no significant 
differences between the AP-FFX and AP-sham mice.  The Αβ load in AP-FFX mice 
averaged 5.4% in the hippocampal formation, ranging from 2.3 % to 9.1 %, while the 
average Αβ load in the AP-sham mice was 5.2 %, with a range from 1.1 % to 7.7 %.  
Further, an analysis of the separate hippocampal regions, i.e. dentate gyrus, CA1 region 
and dorsal subiculum also did not reveal any significant differences between AP-FFX 
and AP-sham animals (II, Figure 4B). 
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5.3. Characterization of learning and memory deficits in AP mice, and its possible 
relationship with amyloid deposition (III) 
5.3.1. Behavioural findings 
All the behavioural findings of study III have been summarized in Table 2. 
Experiment 1 
Win-shift task in the RAM 
In the acquisition phase, all groups of mice showed learning as assessed by the 
total number of errors made until 7th correct choice.  No interaction between trials and 
genotype or lesion was found.  The ANOVA revealed a significant FFX lesion effect, 
but no genotype effect or genotype x lesion interaction (III, Figure 4).  Retention of the 
task learning was reassessed after 2 weeks, and 1.5, 2.5, and 3.5 months, respectively.  
Two daily sessions were run a month apart, so we performed an ANOVA with both the 
month and the day as within-subjects factors.  During the retraining phase, no further 
improvement was observed as testing progressed.  The FFX mice made significantly 
more errors than the sham mice, and in contrast to the acquisition phase AP mice were 
also found to be worse than NT mice.  The genotype x lesion interaction was not 
significant, but the ANOVA revealed a significant day x lesion interaction.  This 
interaction was due to late sessions (2.5 and 3.5 months after the task acquisition), in 
which the AP-sham mice dramatically improved their performance from Day 1 to Day 2 
while both FFX groups showed further impairment.  This day-dependent variation in the 
task performance was further assessed by comparing the performance of AP-sham and 
both FFX groups to NT-sham groups separately on the first and second testing days.  In 
the Day 1 comparison, only the AP-FFX mice differed from the NT-sham mice, 
whereas both the AP-FFX and NT-FFX differed from the NT-sham mice on Day 2 (III, 
Figure 4). 
Elevated plus-maze  
The FFX lesion significantly increased the percentage of time that the mice 
spent in the open arms, indicating a decreased level of anxiety in the FFX mice.  The 
genotype effect was nonsignificant, as was the genotype x FFX lesion interaction (data 
not shown). 
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Spontaneous alternation task in the T-maze 
In the initial experiment the ANOVA revealed a significant decrease in the 
alternation rate of the FFX mice compared with the sham mice (III, Figure 5A, black 
columns); on the other hand, the genotype did not affect the alternation rate 
significantly.  However, the alternation rates were generally low in this task, so that only 
the NT-sham performed slightly above chance level and the AP-FFX mice clearly 
below the chance level.  The mice were also sluggish to move, so that it took up to 30 
min to complete the task.  To rule out low activity and poor motivation-to-explore as 
confounding factors, we replicated the experiment with another group of mice that had 
been food deprived overnight.  This procedure resulted in more active locomotion and 
better alternation rates, and both genotypes performed significantly above chance level 
(III, Figure 5A white columns).  But again no difference was observed between the 
genotypes (III, Figure 5A). 
Experiment 2 
Delayed alternation task in the T-maze 
The cumulative number of errors to the criterion made by the four groups of 
mice is shown in Figure 5B (III).  FFX mice of both genotypes made significantly more 
errors and failed to reach the criterion by the 10th day.  Except for one AP-sham mouse 
and one NT-sham mouse which were excluded for the next session, both groups of 
sham-operated mice reached the criterion within 10 days and did not differ from each 
other in the rate of acquisition.  These mice were tested further in the mixed-delay 
session of the task.  No difference was found between AP and NT mice in performing 
the task with mixed delays ranging from 20 to 100 s.  
Water maze 
The swimming speed of the mice was not affected by FFX lesion or genotype.  
In the overall ANOVA with lesion and genotype as between-subjects factors, the FFX 
lesion significantly increased the latency of the mice to find the platform, but the 
genotype effect on escape latency was not significant.  However, the genotype x lesion 
interaction was significant; therefore this interaction was further examined with 
ANOVAs performed separately for FFX and sham groups.  In this analysis, the AP-
sham mice were found to be inferior to NT-sham mice, but the AP-FFX and NT-FFX  
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mice did not differ from each other.  These results suggest that AP genotype itself can 
impair the task learning to a certain extent and that AP genotype and FFX lesion have 
no additive effects.  The latency of the mice to find the visible platform was also 
analysed.  FFX lesion significantly increased the latency of the mice to find the visible 
platform, but no main effect of the genotype was found nor any genotype x lesion 
interaction. 
Short-term memory vs. long-term memory in the water maze  
As above findings suggested, AP mice are impaired in some but not all tasks that 
are sensitive to lesions of the FFX.  Most notably, the AP-sham mice were normal in 
delayed alternation in the T-maze, although FFX mice showed a robust impairment.  In 
order to distinguish deficits between short-term memory (working memory) and long-
term memory (reference memory), the water maze data were further analysed.  The 
long-term memory component of water maze task was assessed by defining the mean 
latency to platform finding of the first 2 trials on the 2nd, 3rd, 4th and 5th day; while, 
the short-term memory component was assessed by subtracting the latency of the 5th 
trial from the 1st trial (same starting point) over all five testing days.  
With regard to the long-term memory index, the effect of FFX lesion was shown 
to be significant by ANOVA, while the genotype effect was not.  However, the genotype 
x lesion interaction reached significance.  The subsequent separate ANOVAs for the 
lesion groups showed that the AP-sham group was worse than NT-sham mice, but the 
AP-FFX and NT-FFX did not differ from each other (III, Figure 6B).  For the short-
term memory index, the ANOVA revealed a significant effect of the FFX lesion, but no 
genotype effect or genotype x lesion interaction (III, Figure 6C).  
Experiment 3 
Win-stay task in the RAM and position discrimination in the T-maze 
Both NT-sham and NT-FFX mice improved their performance in these two tasks 
over the training days as measured by the total number of errors.  The FFX lesion did 
not affect the task acquisition (III, Figure 7A and 8A) 
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Experiment 4 
Win-stay task in the RAM and position discrimination in the T-maze 
Both AP and NT mice improved their performance over training days as 
measured by the total number of errors.  The ANOVA did not reveal any effect of the 
genotype on acquisition of the task (III, Figure 7B and 8B). 
 
Table 2.  Summary of the behavioural findings of Study III  
 
 
Tasks 
 
NT-sham 
 
 
AP-sham 
 
NT-FFX 
 
AP-FFX 
Win-shift task in RAM: acquisition > N ↓ ↓ 
Win-shift task in RAM: retention > ↓ * ↓ ↓ 
Spontaneous alternation in T-maze > N ↓ ↓ 
Delayed alternation in T-maze > N ↓ ↓ 
Water maze: hidden platform > ↓ ↓ ↓ 
Water maze: visible platform > N †  ↓ ↓ 
Water maze: short-term memory > N ↓ ↓ 
Water maze: long-term memory > ↓ ↓ ↓ 
Win-stay task in RAM > N N N 
Position discrimination in T-maze > N ╪ N N 
Elevated plus-maze: time in open arms > N ↑ ↑ 
 
>: Normal;  N: no impairment/ difference vs. NT-sham;  ↓: impaired vs. NT-sham;   
↑: increased vs. NT-sham;   *: see text;   †: found impaired in Study I;   
╪: found better in Study I. 
 
5.3.2. Amyloid pathology 
Since the Aβ level and Aβ load in the hippocampus did not differ between 18-
month-old AP-FFX and AP-sham mice (II), the data from AP-FFX and AP-sham mice 
were combined for the analysis of the regional distribution and extent of amyloid 
deposition in the brain, which are summarized in Figure 2 of (III).  The dorsal 
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hippocampal formation, more specifically the dorsal subiculum, has the highest density 
of Aβ depositions.  Less severe but notable amyloid deposition was found in all cortical 
areas examined, with a tendency for posterior areas to have a larger amyloid burden 
than the anterior cortical areas.  In contrast, the striatum and thalamus were nearly 
devoid of amyloid pathology even at the age of 18 months. Figure 3 of (III) 
demonstrates three coronal sections from an AP-sham mouse at different levels, 
illustrating the unequal distribution of amyloid deposits.  
5.4. Correlation between Aβ levels in brain, CSF and serum, and cognitive deficits 
in AP mice (IV) 
In the water maze test, the swimming speed did not differ between AP and NT 
mice.  However, the average latency of AP mice to find the hidden platform was 
significantly longer than that of NT mice (not illustrated).  A spatial learning 
impairment of AP mice was confirmed in the probe trial by their reduced search time 
over the previous platform location compared to NT mice (IV, Figure 1A). 
The Αβ  level in all samples of the NT mice (n= 4) was below the detection 
level, verifying the specificity of the used antibody to human Αβ.  Therefore, the 
following correlation analysis was limited to AP mice only (n= 22).  In serum, the Αβ42 
level of the AP mice was below the detection level, but the Αβ40 could be measured. 
Due to the limited amount of CSF obtained, only Αβ42 was measured.  The Aβ level in 
the serum and CSF, the soluble and insoluble Αβ  levels in the brain (hippocampus), and 
the correlations among these Αβ  levels and spatial learning are summarized in Table 1 
of (IV).  The insoluble Αβ40 and Αβ42 levels in the hippocampus were highly 
correlated, and these levels correlated with the level of soluble Αβ42 (IV, Figure 1C); 
however, only the insoluble Αβ42 level was significantly associated with spatial 
learning (IV, Figure 1B).  Neither CSF nor serum Αβ  was significantly correlated with 
spatial learning.  The CSF Αβ42 correlated with the brain soluble Αβ42 level (IV, 
Figure 1D), but not with serum or insoluble brain Αβ  levels.  Serum Αβ40 level was 
not correlated with either CSF or brain Αβ  level. 
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6. DISCUSSION  
6.1. Methodological considerations of the study 
6.1.1. The animal model 
The mouse model of AD that we used, the APPswe and PS1(A246E) double 
transgenic mice, were developed and described by Borchelt et al. in 1997.  These mice 
have elevated levels of the highly fibrillogenic Αβ42 peptide in the brain, and develop 
amyloid plaques starting around the age of 9 months (Borchelt et al., 1997).  The 
formation of amyloid plaques starts in the subiculum and caudal cortex, and later 
extends to hippocampus and all cortical areas.  This feature is somewhat similar to the 
early stages of AD, in which the pathology is also largely restricted to the medial 
temporal cortical structures (Braak and Braak, 1991).   
Principally, we used these mice as the animal model of AD in these studies for 
two reasons:  
1) They provide a good model for studying the metabolism of Aβ, since they 
have elevated levels and deposits of Aβ that are restricted to the cortex and the 
hippocampus.   
2) They develop amyloid pathology at a relatively late age, i.e. around 9 months 
of age, which gives a good window of opportunity for testing potential therapeutics for 
AD.     
6.1.2. Choice of metrifonate for the chronic treatment 
Metrifonate (MTF) is a prodrug that is hydrolyzed non-enzymatically to 2,2-
dimethyl dicholorovinyl phosphate (DDVP), which provides a sustained inhibiton of 
AChE by binding stably to the catalytic site of the enzyme (Reiner et al., 1975).  As a 
second generation ChEI, metrifonate, has been shown to improve cognitive performance 
of AD patients in clinical trials (Cummings et al., 1998a; Farlow and Cyrus, 2000), and 
in preclinical studies it was demonstrated to raise brain ACh levels (Mori et al., 1995a) 
and to have beneficial effects on learning and memory, both in rats and mice (Riekkinen 
et al., 1997; Ikonen et al., 1999).  
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We chose to use metrifonate as ChEI to investigate whether chronic treatment 
with a ChEI could decrease Aβ production for three reasons:   
1) Metrifonate provides a relatively stable and long-term inhibition of ChE with 
one daily dose, and its unique property of action allows for a well-tolerated 
inhibition of ChE over longer time period compared with other drugs that are 
already on the market (such as donepezil, rivastigmine) (Ringman and 
Cummings, 1999; Schmidt and Heinig, 1998). 
2) Cell cultures studies have shown that metrifonate modulates APP 
metabolism into the less amyloidogenic direction (Pakaski et al., 2000).    
3) Previous studies in our group have used this drug in mice with the same 
genetic background (C57BL/6J) (Ikonen et al., 1999). 
6.1.3. Cholinergic depletion of the hippocampus by fimbria-fornix transection 
In order to investigate the effects of cholinergic dysfunction on APP processing 
in the hippocampus, a fimbria-fornix lesion model was used. The fimbria-fornix carries 
the largest part of cholinergic afferents to the hippocampal formation (approximately 
75%) (Storm-Mathisen and Guldberg, 1974).  In rats, a fimbria-fornix lesion has been 
demonstrated to result in a dramatic depletion of cholinergic markers in the 
hippocampus (Henderson, 1996).  It should be noted that AChE staining disappears 
completely in the dorsal hippocampus after transection of the fimbria-fornix, but the 
cholinergic staining in the ventral hippocampus is partially retained (Gage et al., 1984; 
Gaykema et al., 1990).  Compared to other alternatives for the cholinergic depletion of 
the hippocampus, the FFX-transection model was chosen for two reasons:     
1) The lesion effect of FFX-transection is similar to that induced by other 
alternative lesion methods, such as electrolytic or excitotoxic lesion of the 
cholinergic basal forebrain (Cassel et al., 1997), but the outcome is more 
consistent. 
2) Producing selective cholinergic lesions with immunotoxin in mice was not 
possible at the time point when our experiment was carried out, as the 
available immunotoxin, i.e. 192 IgG-saporin, only works well in rats. 
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6.1.4. Choice of behavioural tests 
 For the behavioural phenotyping of the AP mice, we used a battery of 
behavioural tasks, which are varying both in nature and in the sensorimotor functions 
required.  The open field test was used first, primarily as a preliminary screening in 
order to detect possible deficits of the transgenic mice in locomotor functions, and the 
elevated plus-maze test was used to test for changes in emotional status (i.e. anxiety).  
Thereafter, the mice were tested in different learning and memory tasks.  Several 
appetite-motivated learning and memory tasks were used.  Among these, the win-shift 
version of RAM task and delayed alternation task in the T-maze were used to measure 
spatial working memory, whereas the win-stay version of RAM and position 
discrimination in the T-maze task were employed to detect non-spatial learning and 
memory.  In addition, spontaneous alternation task in the T-maze was conducted to 
assess exploratory behaviour and working memory, which is based on the animal’s 
natural tendency to explore novelty.  The Morris water maze task was used to 
specifically detect impairment in hippocampal-dependent spatial learning and memory 
(Morris et al., 1982), and this task is primarily aversively motivated.  In order to 
minimize confounding factors such as carry-over or interference, we have divided the 
mice into subgroups and tested them with a limited number of tasks only. 
6.2. Effects of cholinergic manipulation on APP and Αβ levels, and the deposition 
of  Αβ  
6.2.1. Inhibition of AChE by metrifonate failed to prevent the marked overproduction 
and deposition of Aβ, and the spatial memory deficits in AP mice 
In this study, seven-month-old AP mice were chronically treated with 
metrifonate (MTF) for 7 months at a dose (100mg/kg) that has been found to lead to 
81% inhibition in the activity of AChE after acute administration.  At the end of the 
treatment period, the level of inhibition of AChE was found to be approximately 50%; 
however, the total APP levels in the hippocampus were not altered by MTF in both AP 
and NT mice.  No reduction in the Aβ40 or Aβ42 level was observed in the MTF 
treated AP mice; in contrast to our hypothesis, MTF  significantly increased Aβ levels 
in the hippocampus.  These findings do not support the suggestion derived from in vitro 
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studies that ChEI treatment would slow down amyloid production in the brain. Our 
results appear at odds with recent in vitro findings that ChEIs (including MTF) (Pakaski 
et al., 2000) promote APP processing through the α-secretase pathway and thus limit 
the production of Aβ (Mori et al., 1995b).  They also contrast with the findings that 
direct stimulation of muscarinic (Nitsch et al., 1992) or nicotinic (Kim et al., 1997) 
receptors leads to increases in the production of soluble APP in vitro.  The discrepancy 
between these in vitro studies and the present in vivo study may be explained by several 
mechanisms.  First, chronic treatment with ChEIs may not result in a sufficient increase 
in synaptic ACh level compared to short-term treatment.  Chronic inhibition of AChE is 
likely to result in upregulation of the enzyme; the fact that AChE inhibition was 
decreased from 81% (short-term) to about 50% at the end of our experiment, and that 
increased staining of AChE could be seen in some neurons indicate that an increased 
AChE synthesis may be present.  Further, the increased levels of ACh can reduce its 
own release through stimulation of M2 autoreceptors; indeed, it has been shown in brain 
slices that nonselective muscarinic stimulation with carbachol does not increase the 
secretion of sAPP unless M2 receptors are simultaneously blocked (Farber et al., 1995).  
Second, synthesis of ACh by ChAT is limited by the high-affinity uptake of choline, 
which in turn is partially derived from the extracellular breakdown of ACh by its 
esterase; prolonged inhibition of AChE could thus reduce ACh synthesis.  Third, a 
chronic increase in the ACh level in the intact brain may have additional effects that 
could cancel the (beneficial) direct effects on APP metabolism; in other words, the APP 
processing in vivo may be only partially under the regulation of cholinergic activity.  
Finally, it is possible that the processing of the human APP was regulated differently 
from the endogenous mouse APP.  To elucidate the relationship between APP 
processing and cholinergic activity, a study that specifically investigates the effects of 
cholinergic depletion on APP processing in AP mice is needed.  
Although a significant increase in the total amount of Aβ40 and Aβ42 in the 
hippocampus was found in the MTF treated AP mice; however, the number of amyloid 
plaques in the hippocampus did not differ from the vehicle treated AP mice.  This 
finding may be partly due to the fact that separate sets of animals were used for 
biochemical and neuropathological analysis, or that the number of animals in the 
neuropathological analysis was relatively small.  An alternative explanation is that this 
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discrepancy may be related to the decreased Aβ42 to Aβ40 ratio in the MTF treated 
animals. A recent report (Mucke et al., 2000) comparing different APP transgenic 
mouse lines found that a high Aβ42 to Aβ40 ratio is more favourable for plaque 
formation.  Interestingly, in an in vitro study, MTF reduced the amount of Aβ42 
secreted into the conditioned medium but had no effect on the amount of Aβ40 (Lahiri 
et al., 2000).  This was not observed in other equipotent ChEIs, suggesting that MTF 
may modify γ-secretase activity through a mechanism that is independent of its action 
on AChE.   
The present study demonstrated that the AP mice were impaired in the spatial 
version of the water maze, which could indicate compromised functioning of the 
hippocampus (Morris et al., 1982). However, it should be noted that the AP mice were 
also impaired in the cued version of the water maze task, which is consistent with the 
original observation by Morris (1982) that rats with hippocampal lesions were also 
impaired in the initial learning in the visible platform version of the task.  Notably, such 
deficits have been demonstrated to be independent of age in an earlier study (Puoliväli 
et al., 2002).  Further, in this study no motor abnormalities were observed in the AP 
mice, and their swimming speed was similar to that of the controls.  Since all transgenic 
AP mice could find the visible platform, their inferior performance in this task is 
unlikely caused by an impaired visual ability (Puoliväli et al., 2002), but more likely by 
a deficit in learning a new task.  Similar to our previous study, AP mice that failed in the 
visible platform task often swam towards the platform, but went on swimming after they 
hit it (Puoliväli et al., 2002).   
In contrast to water maze learning, AP mice performed the place discrimination 
task in the T-maze better than NT mice; the learning of this task requires egocentric 
memory, which has been suggested to require intact functioning of the striatum 
(Oliveira et al., 1997).  A better performance of AP mice in such a striatum-dependent 
task might reflect a compensatory effect due to the impaired functioning of the 
hippocampal formation.  On the other hand, our previous study demonstrated that 
younger AP mice (12-month-old) performed the same task equally to the NT control 
mice (Puoliväli et al., 2002).   
The behavioural effects of chronic treatment with a relatively large dose of MTF 
in the AP mice were not very favourable, since it did not improve the performance in 
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any of the learning and memory tasks employed.  In general, the drug was well tolerated 
in the mice, but it clearly decreased locomotor activity in the open field, and reduced 
swimming speed in the water maze.  These effects most likely reflect muscle weakness 
due to peripheral effects of MTF at the neuromuscular junction; muscle weakness is a 
common symptom of excessive inhibition of AChE due to organophosphate poisoning 
(He et al., 1998; Singh and Sharma, 2000). It is possible that the decreased swimming 
speed could have masked a beneficial effect of MTF in the water maze learning.   
Finally, it should be noted that one important difference between our mouse 
model and human AD is the extensive cholinergic degeneration in AD patients as 
opposed to the absent (or possibly, very mild) cholinergic dysfunction in our mice. In 
the AP mice, the brain ChAT activity, the density and distribution pattern of the AChE 
positive fibers, and the binding levels of α4β2 and α7 nAChRs are not different from 
their nontransgenic controls (I, II and Marutle et al., 2002), indicating that no obvious 
cholinergic changes exist in the AP brain. This might also explain the lack of beneficial 
effect of MTF on water maze performance of the AP mice, as in previous studies of our 
laboratory, MTF dose-dependently improved water maze performance only in mice with 
medial septal lesions but did not affect the performance of sham-operated mice (Ikonen 
et al., 1999).  However, based on the currently available data, we cannot entirely 
exclude a possible role of cholinergic dysfunction in causing the memory impairment in 
our AP mice.  In fact, cholinergic changes have been reported in several other 
transgenic mouse models.  For instance, in the APP+PS1(M146L) mouse, a prominent 
decrease in the density of cholinergic synapses in the frontal cortex and a reduction of 
size of these synapses in the frontal cortex and hippocampus have been observed (Wong 
et al., 1999).  In the Tg2576 mice, Apelt et al. demonstrated (Apelt et al., 2002) a 
significant reduction of high-affinity choline uptake in the hippocampus in 21-month-
old mice, and reduced binding levels of M1- and M2-muscarinic cholinergic receptors 
in the cortex and hippocampus, but there was no difference in the level of AChE and 
ChAT activity in the cortex or hippocampus between transgenic mice and non-
transgenic littermates, at any age between 7 and 24 months (Apelt et al., 2002).  For our 
AP mice, besides the ChAT activity or AChE staining, other parameters that are related 
to the cholinergic neurotransmission, such as synaptic ACh level, binding levels of M1- 
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and M2-muscarinic cholinergic receptors, high-affinity choline uptake, and the possible 
changes of cholinergic synapses, etc., should also be studied in the future. 
6.2.2. Fimbria-fornix lesion does not affect APP levels and amyloid deposition in the 
hippocampus of AP mice 
The fimbria-fornix transection resulted in a substantial depletion of cholinergic 
markers in the hippocampus at all three time points studied, and the extent of 
cholinergic depletion was similar for both transgenic and control mice.  A more than 
70% decrease in ChAT activity was found 2 weeks and 3 months postlesion, but the 
decrease was reduced to only 52% following an 11 months recovery period. The AChE 
staining density in the hippocampus was also higher in the 18-month-old animals 
compared to the 8 month-old mice (i.e. 11 vs. 3 months postlesion).  The recovery of 
cholinergic markers after a long-term survival period has been observed in earlier 
studies in rats (e.g. Gage et al., 1983).  They demonstrated a reinnervation of the 
hippocampus by the undamaged ventral afferent axons (Gage et al., 1984; Gasser and 
Dravid, 1987), and this likely also occurred in our mice.   
Despite the marked cholinergic depletion (> 50-70 %) of the hippocampus, total 
APP or Αβ levels were not significantly changed in the hippocampus at either of the 
time points studied.  Further, the lack of change in the level of either sAPP or mAPP 
indicated that probably APP processing was not altered by the lesion.  Moreover, the 
extent of Αβ deposition did not differ between the 18-month-old AP-FFX and AP-sham 
mice (i.e. 11 months postlesion), as assessed by plaque counts and analysis of the Αβ 
load.  Taken together, our data suggest that transection of the fimbria-fornix does not 
substantially alter APP processing in the hippocampus and, thus, does not accelerate or 
decrease Αβ production (or deposition) in the hippocampus of our AP mice. 
The relationship between cholinergic denervation and APP metabolism is not 
clear yet; some studies have shown an increase in APP levels, whereas other studies 
demonstrated a decrease.  Ramirez et al. (2001) reported that APP mRNA levels were 
reduced in the hippocampus after selective lesions of the cholinergic medial septum in 
rats.  Similarly, Apelt et al. (1997) showed that 192-IgG-saporin induced basal forebrain 
cholinergic lesion moderately decreased levels of APP695 mRNA but not APP 751 or 
APP770 isoforms in the cortex and hippocampus in rats.  In contrast, Rossner et al. 
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(1997) did not detect significant changes in total APP mRNA levels after selective 
lesions of the cholinergic basal forebrain in rats, although a significant reduction of 
secreted APP and a concomitant increase of membrane-bound APP were observed.  
However, these findings together with our findings are at odds with other previous 
studies demonstrating increased APP expression after lesions of the basal forebrain 
cholinergic system in different mammalian species.  For instance, in rats cholinergic 
basal forebrain lesions, produced by NMDA injection, have been reported to increase 
APP mRNA and APP synthesis in the cortex (Wallace et al., 1991; Wallace et al., 
1993).  Similarly, selective lesions of the cholinergic neurons of the basal forebrain 
have also been reported to increase APP gene expression and protein level in various 
cortical and hippocampal regions (Leanza, 1998; Lin et al., 1998).  The discrepancies 
between these results may likely be attributed to the different time points studied, the 
type of lesion, or the methods of measuring APP.  
With regard to the alterations in Aβ levels and/or Aβ deposition after cholinergic 
lesion, two recent studies reported contradictory results.  Beach et al. (2000) lesioned 
the nucleus basalis of magnocellularis (nbM) in 12-week-old rabbits, which resulted in a 
2.5-and 8-fold increase in the levels of cortical Aβ40 and Aβ42, respectively.  In 
contrast, Boncristiano et al. (2002) performed unilateral nbM lesions in adult, transgenic 
APP23 mice, and they found a significant decrease in Aβ levels (19%) in the ipsilateral 
frontal cortex compared with the contralateral side.  These discrepant results may likely 
be attributed to the overexpression of APP in the transgenic mouse compared to the 
normal expression level of APP in the rabbit, but it is also possible that species 
differences have an influence on APP metabolism.  For example, phorbol ester 
activation of PKC has been shown to increase the release of sAPP and decrease Αβ 
release in rat cell cultures or other cell lines (Buxbaum et al., 1993b; Caputi et al., 1997; 
Gabuzda et al., 1993); but in the brains of transgenic mice producing elevated levels of 
human Αβ, activation of PKC decreased both sAPP-β and Αβ levels without affecting 
sAPP-α levels (Savage et al., 1998).  Alternatively, the overproduction of Aβ due to the 
APPswe mutation (Citron et al., 1992) may mask the possible mild alteration in Aβ 
levels induced by the fimbria-fornix lesion.   
Taken together, our findings indicate that disruption of cholinergic 
neurotransmission does not seem to promote the progression of AD-like amyloid 
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pathology in the hippocampus in AP mice, contrary to what has been suggested by 
earlier studies (e.g. Wallace et al., 1993; Lin et al., 1998; Leanza, 1998 #163). 
Considering the non-specific nature of the fimbria-fornix lesion, further investigation is 
still needed to examine the effects of pure cholinergic dysfunction on APP metabolism 
and the progression of Aβ pathology, when the highly selective cholinergic lesion 
approach with IgG-saporin is available also for mice (Berger-Sweeney et al., 2001). 
6.3. Learning and memory impairments in AP mice, and their relation to 
Aβ overproduction and deposition  
6.3.1. Hippocampus-dependent long-term spatial memory is selectively impaired in 
AP mice that develop amyloid pathology mimicking early stages of AD 
The aim of this study was to elucidate the behavioural consequence of amyloid 
deposition in the 17-month-old AP mice. The results of the histopathological study 
confirm earlier observations (Borchelt et al., 1997) that amyloid deposition in these 
mice is largely restricted to the hippocampal formation and the neocortex, with the 
earliest deposits in the dorsal subiculum.  In contrast to the more widely used 
APP+PS1(M146L) double transgenic mouse (Arendash et al. 2001; Gordon et al., 2001; 
Gordon et al., 2002), very few amyloid deposits were found in the striatum and 
thalamus at any age in our AD  mouse model.  Thus, in some aspects, our AP mouse is 
a good model for the early stages of Alzheimer’s disease in which the pathology is most 
prominent in medial temporal lobe structures (Braak and Braak, 1991); however, it 
should be noted that the mouse does not develop neurofibrillary tangles. 
To test whether the amyloid pathology in the hippocampal formation would 
have a functional correlate, we tested AP mice in a large battery of learning and 
memory tasks, and, further, we compared the behavioural profile of AP mice with 
fimbria-fornix lesioned mice.  The comparison between AP mice and fimbria-fornix 
lesioned mice revealed interesting similarities.  First, both AP and FFX mice performed 
similar to their controls in two non-hippocampal dependent tasks, i.e. the win-stay task 
in the 8-arm radial maze and in the position discrimination task in the T-maze (Table 2).  
In rats, both tasks have been suggested to be sensitive to striatal lesions but not to 
hippocampal lesions (Oliveira et al., 1997; Packard et al., 1989).  Normal performance 
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of the AP mice in these two tasks is consistent with the minimal pathology in the 
striatum in these animals.  Second, both AP and FFX mice were impaired in the water 
maze task, which is hippocampus-dependent.  Remarkably, this impairment is selective 
to the long-term memory component of the water maze task, as the AP mice improved 
their performance comparably to that of the NT control mice during each daily session.   
Interestingly, in addition to the hidden platform task, FFX mice also performed worse in 
the visible platform task than the sham-operated control mice.  It is possible that the 
earlier experience in the hidden platform training interfered with the learning of the 
visible platform task in the FFX mice (Gerlai, 2001).  
However, in sharp contrast to the impaired performance of FFX mice, AP mice 
(i.e. AP-sham) performed comparably to NT control mice in the win-shift version of the 
radial arm maze task, and in both spontaneous and food motivated delayed alternation 
tasks in the T-maze.  Common to these tasks is that they all require intact spatial 
working memory and have been shown to be sensitive to damage of the hippocampal 
formation.  One could argue that impaired performance of AP mice in the water maze, 
but relatively normal performance in dry mazes, is due to the aversive nature and the 
stress associated with swimming.  However, two observations in this study strongly 
argue for a memory deficit in the AP mice rather than increased sensitivity to stress in 
the aversive water maze tasks.  First, AP mice showed normal short-term memory in the 
water maze task, as their improvement within the day was not different from that of 
controls, but, in contrast, their memory retention for the platform location on the next 
day was clearly impaired.  Second, AP mice were unimpaired in two different T-maze 
alternation (working memory) tasks that differed in the motivational aspect.  Whereas 
the delayed alternation was food-motivated as were all radial arm maze tasks, the 
spontaneous alternation is based on the innate explorative behaviour of mice in a novel 
environment.  Hence, the likely explanation of the behavioural profile of the AP mice is 
to conclude that they were impaired in hippocampal dependent tasks but only in those 
that tax long-term memory.  
The only task in which the AP genotype and FFX lesion appeared to have 
additive effects was the retention phase of the win-shift version of the RAM task.  In 
this task the AP-FFX group was clearly worse than any other group.  The nature of this 
additive effect may be explained when we compare the performance of AP-sham and 
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NT-FFX groups over two testing days (III, Figure 4).  In the last two sessions, the AP-
sham mice made as many errors as AP-FFX mice on Day 1, but they dramatically 
improved their performance on Day 2.  It looks as if these mice had forgotten the rule of 
the task after a pause of one month in the testing routine, but performed as controls on 
Day 2 after re-training in the task.  Such rule learning may not depend on the 
hippocampus as much as on frontal and parietal cortices that were intact in NT-FFX 
mice but loaded with amyloid in the AP-sham and AP-FFX mice.   
The selective impairment of hippocampal dependent long-term memory is at 
odds with other studies in APP mutant mice or APP+PS1(M146L) mice that reported 
impaired working memory in the tasks of radial arm water maze (Arendash et al., 2001), 
the win-shift version of the RAM (Dodart et al., 1999), and delayed alternation in the T-
maze (Chapman et al., 1999).  However, this discrepancy might be related to the 
differences in the mouse strain that was used to generate transgenic mice (Crawley et 
al., 1997), or differences in the type, amount, or localization of the amyloid pathology in 
these animal models.  It is noteworthy that the densest amyloid deposition in our AP 
animals is found in the dorsal subiculum; based on selective lesions of either 
hippocampus or subiculum, Morris et al. (Morris, 1990) suggested that subicular lesions 
may cause an impairment of long-term spatial memory in the water maze navigation but 
little impairment in spatial short-term memory.  Rats with subicular lesions have been 
reported to be impaired in the working memory version of the RAM, but the impairment 
is less severe than in rats with hippocampal lesions (Galani, 1998).  It should be noted 
that the only study with selective subicular lesions in mice showed increased reference 
but not working memory errors in a modified RAM task (Cho and Jaffard, 1995).  
Further, different stages of amyloid pathology may have distinct effects on memory 
processes.  All studies that have reported impaired working memory used transgenic 
animals with higher amounts of Aβ deposits compared to our mice (Arendash et al., 
2001; Chapman et al., 1999; Dodart et al., 1999).  For instance, the APP+PS1(M146L) 
mice at 15-16 months age have an average amyloid load of approximately 50 % in the 
frontal cortex, while that in our mice never exceeds 5% at the age tested (17 months).  
Large amyloid deposits with surrounding inflammatory reaction (Stephan et al., 2001) 
may have non-selective effects on nearby neurons, whereas a less robust accumulation 
of Aβ may more selectively interfere with neuronal plasticity.  Several mechanisms 
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have been proposed by which Αβ may interfere with neuronal plasticity without direct 
neurotoxicity. For example, intracellular calcium signaling plays a pivotal role in 
learning induced plasticity, and Aβ has been shown to destabilize calcium homeostasis 
in neurons (Mattson et al., 1992).  Elevated levels of Aβ may also downregulate the 
mitogen-activated protein kinase (MAPK) cascade and decrease phosphorylation of 
cAMP-response element binding protein (CREB) (Dineley et al., 2001; Tong et al., 
2001), which plays an essential role in learning and memory processes (reviewed by 
Silva et al., 1998). In addition, both APP and its C-terminal fragment containing the Aβ 
peptide are axonally transported to the axon terminals where it may interfere with 
synaptic transmission (Buxbaum et al., 1998), or with critical signal transduction 
processes that mediate neuronal plasticity.   
6.3.2. Cognitive deficits in AP mice correlate with insoluble Aβ42 level, but not with 
the soluble Aβ42  level in the brain, or with the Aβ  levels in CSF and serum  
The primary aim of this study was to investigate the relationship between Aβ 
levels of different forms (i.e. soluble and insoluble) and species (i.e. Αβ40 and Αβ42) in 
brain (hippocampus) and the spatial learning and memory deficits in AP mice.  Our 
results demonstrated that it is Αβ42 but not Αβ40, and it is the levels of insoluble but 
not soluble form of Αβ42 that correlate with impaired spatial memory, as shown by a 
decreased search bias in the water maze. This result confirms the previous finding of 
our laboratory in AP mice that the concentration of total Αβ42 but not that of soluble 
Αβ42 in the hippocampus correlates with impaired spatial memory in the water maze 
(Puoliväli et al., 2002).  This study also demonstrated that at the age of 12 months, the 
memory impairment was not correlated with Aβ load or plaque number in the 
hippocampus (Puoliväli et al., 2002).  Our results substentiate the previous findings 
showing that aggregated form of the Aβ peptide is the primary neurotoxic agent both in 
vitro (Lorenzo and Yankner, 1994; Pike et al., 1993) and in vivo (Giovannelli et al., 
1998).  They are also in accordance with a very recent study that demonstrated that 
neuronal loss is associated primarily with thioflavin S-positive fibrillar Aβ deposits 
(Urbanc et al., 2002) in both AD patients and transgenic mice.  However, the results of 
our studies are slightly different from an earlier study in AD patients demonstrating that 
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elevated levels of both total Αβ42 and Αβ40 in the neocortex are correlated with 
cognitive decline (Näslund et al., 2000).  This may be explained by the difference in 
genetic background between transgenic mice and humans, or the expression of the 
mo/hu APP-695swe in the AP mice.  Further, the ratio of Αβ42 and Αβ40 is quite 
different between humans and mice (Näslund et al., 2000). On the other hand, 
immunocytochemical studies of the AD brains have revealed that it is Αβ42 (and Αβ43) 
that deposits very early in the disease process, and this is associated with the cognitive 
decline (Parvathy et al., 2001), strongly indicating a higher neurotoxic effect for Αβ42 
than for Αβ40.  In contrast, McLean et al. reported that cognitive deficits correlated 
only with soluble but not insoluble Αβ (McLean et al., 1999), suggesting that more 
studies are needed to clarify the current discrepancies.   
To achieve an early diagnosis of AD and monitor the disease progress, 
considerable attempts have been made to find a reliable biomarker for AD.  Among the 
several candidates (such as CSF Αβ, tau, and plasma Αβ etc.) the relationship between 
Αβ levels in the cerebrospinal fluid (CSF) and the presence and/or severity of the 
disease has been most intensively studied.  The results have been variable showing a 
decrease (Pirttilä et al., 1994), an increase (Nakamura et al., 1994) or no change (Motter 
et al., 1995; Nitsch et al., 1995; van Gool et al., 1995) in total Aβ levels.  In longitudinal 
studies, CSF Αβ levels were shown to be stable during a follow-up period of one year 
(Andreasen et al., 1999), but to decrease during an extended follow-up (Tapiola et al., 
2000).  The decrease in the CSF Αβ level may reflect the deposition of Αβ in the brain 
(Kawarabayashi et al., 2001) and hence the reduced efflux of Aβ from brain to CSF.  
This notion is supported by a recent study in Tg2576 APPswe transgenic mice that 
demonstrated an inverse-correlation between the Αβ levels in CSF and brain as mice 
age, i.e. Αβ42 levels in the CSF decreased at the age when there is marked amyloid 
deposition in the brain (Kawarabayashi et al., 2001).  However, the relationship between 
CSF Αβ and the severity of cognitive deficits in AD patients is currently unclear, 
showing either an inverse correlation (Hock et al., 1998; Nitsch et al., 1995) or no 
correlation (Andreasen et al., 1999; Nakamura et al., 1994).  So far, in transgenic mouse 
models of AD, the possible correlation between the CSF Aβ level and memory deficits, 
and, more importantly, the relation between CSF Aβ level and brain Aβ burden have 
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never been studied.  Therefore, we correlated CSF Aβ levels with those of the brain, as 
well as with the water maze learning.  The results revealed a significant correlation 
between CSF Αβ42 level and brain soluble, but not insoluble, Αβ42 level; on the other 
hand, the CSF Αβ42 levels are not correlated with the spatial learning deficits in the 
water maze tasks (IV, Table 1). Together, these results suggest that the measurement of 
CSF Αβ42 may not be a good indicator for the cognitive decline.  However, 
longitudinal studies are still needed to further elucidate the relationship between 
changes in the CSF Αβ42 level and the progression of amyloid deposition in AP mice. 
 Controversy still exists whether the Αβ that is present in the CSF is produced 
only by neurons.  It may partly originate from blood cells, e.g. platelets release Αβ on 
activation (Smith et al., 2001) and intravenously injected Αβ can enter brain through the 
blood-brain-barrier (Maness et al., 1994).  The situation is likely different in the present 
study.  The prion protein promoter used in our mice directs transgene expression to 
practically all tissues, but at high levels only in brain and heart (Borchelt et al., 1996a); 
therefore, neurons are likely to be the main source of Αβ in the CSF of our AP mice, but 
the heart cannot be excluded.   
In this study, we also examined the relation between Aβ levels in serum, CSF, or 
brain, and the spatial learning deficits. Since Αβ42 in serum was under the detection 
level of the ELISA kit we used, only Αβ40 was measured.  Our results showed that the 
serum Αβ40 was not correlated with any of the above parameters (IV, Table 1), which is 
consistent with the study in PDAPP transgenic mice (DeMattos et al., 2002), as with a 
study in AD patients (Mehta et al., 2000).  The poor relation between serum and CSF 
Αβ levels, or serum and brain Αβ levels may arise from a difference in the rate of 
clearance of Αβ or a compromised (i.e. decreased) permeability of Αβ across the blood-
brain barrier.  Another possibility is a significant contribution from a non-neuronal 
source, such as the heart, to the total Αβ in serum.  Since we measured Αβ40 in the 
serum and soluble Αβ42 in the CSF and brain this could play a role; however, this is 
likely not the case since the Αβ40 and Αβ42 levels in the brain of our AP mice are 
highly correlated.  Together, these results suggest that the measurement of serum (or 
plasma) Αβ40 may not be a useful biomarker for the diagnosis of AD. 
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The possible relationships in the distribution of soluble and insoluble Aβ among 
different compartments, i.e. brain, CSF and blood were schematically summarized in 
Figure 8. 
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            Figure 8.  A schematic diagram showing the putative relationships in the 
distribution of soluble and insoluble Aβ  among the brain, CSF, and 
blood compartments. 
       
6.4. General discussion  
Using the APPswe and PS1(A246E) double transgenic mouse model of AD that 
have Aβ deposition in their brains as they age, the present studies were aimed to 
investigate the potential role of altered levels of ACh in the regulation of APP 
metabolism and the progression of amyloid pathology, the role of Aβ overproduction 
or/and deposition in causing cognition decline, and, finally, the correlation between 
cognitive impairments and Aβ levels in different compartments (i.e. in brain, CSF, or 
blood).   
In the first study, we showed that an increase in the levels of ACh, induced by 
long-term treatment with metrifonate, did not affect the APP levels in the brain.  
However, presumably via a mechanism that is independent of its action on AChE, 
metrifonate significantly increased both Aβ40 and Aβ42 levels in the hippocampus, but 
reduced the Aβ42 to Aβ40 ratio, without affecting the number of amyloid plaques in the 
hippocampus (I).  Correspondingly, in the second study we demonstrated that a 
sustained decrease in ACh levels in the hippocampus, produced by a fimbria-fornix 
lesion, did not significantly affect hippocampal APP levels and Αβ production, and 
Αβ deposition (II).  Taken together, our results do not support the postulation that 
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modulating ACh levels could significantly alter APP metabolism and Aβ production, or 
the putative role of cholinergic dysfunction in the promotion of Aβ production and 
deposition, which are contrary to previous in vitro or in vivo studies (e.g. Nitsch et al., 
1992; Pakaski et al., 2000; Wallace et al., 1993; Leanza, 1998; Lin et al., 1998).  
Although our results do not support the hypothesis of a causative role of cholinergic 
dysfunction in the pathogenesis of AD, one should be cautious when extrapolating these 
results to human studies, as our AP mice express a chimeric mo/hu APP-695swe cDNA 
on the background of the mouse APP gene. Thus, the expression of mo/hu APP and the 
regulation of its processing in these mice should be different from humans.  Further, 
considering the non-specific nature of the fimbria-fornix lesion and the possible 
differences in APP regulation in different species, more studies are needed to examine 
the effects of cholinergic dysfunction on APP metabolism and the progression of Aβ 
pathology in a higher mammalian species (e.g. monkey) that have the same APP 
sequence as humans.  
The third study of the thesis demonstrated a selective impairment of 
hippocampus-dependent long-term spatial memory of the AP mice in the water maze 
task (III).  A more recent study of our lab has demonstrated that such a learning 
impairment is possibly related to a more rapid decay of long-term potentiation (LTP) in 
the hippocampus (K. Gurevicius et al., unpublished data), but the exact mechanism 
behind the cognitive deficits in our AP transgenic mice is not clear yet.  Based on the 
currently available data, we cannot entirely exclude a possible role of cholinergic 
dysfunction in causing the memory impairment in our AP mice, as some cholinergic 
deficits have already been observed in several other AD model mice (e.g. Apelt et al., 
2002; Wong et al., 1999).  It has been demonstrated by a number of in vitro studies that 
the soluble form of Aβ can reduce ACh synthesis and/or ACh release at a lower 
concentration, while higher concentrations of Aβ can be directly neurotoxic to the 
cholinergic neurons by disrupting intracellular ion concentrations (e.g. Ca2+) and by 
generating reactive oxygen species (reviewed by Auld et al., 1998).  Further, it has been 
demonstrated that microinjection of fibrillar Aβ causes degeneration of basal forebrain 
cholinergic neurons and a concomitant decrease in ACh release in rats (Harkany et al., 
1995a; Harkany et al., 1995b).  On the other hand, it should also be noted that the 
“cholinergic hypothesis” as such is being challenged now by several recent studies. For 
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example, two postmortem studies reported that ChAT activity was upregulated in 
subjects with mild cognitive impairment (DeKosky et al., 2002), and unchanged in early 
stage AD compared with control subjects (Davis et al., 1999), respectively, while a 
decrease in ChAT activity was only found in the relatively late stage of AD (Davis et al., 
1999; DeKosky et al., 2002).  Together, these studies suggest that cholinergic 
dysfunction is likely not responsible for the early cognitive deficits that occur in AD. 
Furthermore, in the fourth study we found that the impaired spatial memory in 
AP mice is significantly correlated with the level of insoluble Αβ42, but not that of 
soluble Αβ42, in the hippocampus (IV), suggesting that the age-related cognitive 
deficits in AP mice are likely related to the overproduction and deposition of Aβ. 
Whereas several studies have shown that there is not a clear relation between the 
amount of deposited Aβ and memory disturbances (e.g. D'Hooge et al., 1996; Holcomb 
et al., 1998; Koistinaho et al., 2001; Moechars et al., 1999), our study (and studies of 
others, e.g. Gordon et al., 2001; Chen et al., 2000) demonstrated that memory 
impairments correlate with insoluble Aβ levels (and deposits) in the brain in middle-
aged AP mice (as discussed in section 6.2.1 and 6.2.2).  Although it is still controversial 
which form of Aβ (soluble or insoluble) is pivotal for the dementia in AD, earlier 
studies have focused on the neurotoxic effects of insoluble Aβ.  Now it becomes 
gradually more accepted that different forms of Aβ may play distinct roles in AD 
pathogenesis.  Increasing evidence suggests that it is soluble oligomer form of Aβ, but 
not the insoluble fibrillar form of Aβ, that causes the prominent hippocampal synaptic 
dysfunction seen in the earliest stages of AD (Selkoe, 2002).   In AD, the monomers of 
Aβ undergo a complex process of fibril formation, during which they exist in the forms 
of soluble oligomers, protofibrils, and fibrils (Walsh et al., 2002b).  Walsh et al. (2002a) 
demonstrated that intracerebroventricular microinjection of soluble oligomers of Aβ, 
but not monomers or insoluble Aβ fibrils, can potently inhibit hippocampal long-term 
potentiation in adult rats, supporting the role of soluble oligomers of Aβ in causing the 
cognitive decline in the early stages of AD.   However, it should be noted that it is 
difficult to test this hypothesis in transgenic mice because a mixture of Aβ forms 
(including monomers, soluble oligomers, insoluble amyloid fibrils, etc) are present in 
the brain (Selkoe, 2002), and they cannot be differentiated by the currently available 
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ELISA for Aβ.  This could also possibly explain the lack of correlation between soluble 
Aβ42 and spatial learning deficits of the AP mice found in the present study (IV).  On 
the other hand, the later forms of Aβ, mainly insoluble Aβ fibrils, are proposed to be 
principally responsible for the neuronal dysfunction and neuronal loss in the late stage 
of AD (Selkoe, 2002; Walsh et al., 2002b).   
Regardless of the different roles of soluble and insoluble Aβ, it seems that 
therapeutics targeted to both Aβ forms could prevent the cognitive decline as 
demonstrated by several recent studies showing that immunization against Aβ can 
protect transgenic mice from learning and memory impairments (Janus et al., 2000; 
Morgan et al., 2000; Dodart et al., 2002).  The results of Janus et al. (2000) and Morgan 
et al. (2000) indicate that the cognitive improvements are largely related to the reduction 
of the Aβ burden; whereas Dodart et al. (2002) reported that passive immunization 
could rapidly reverse memory deficits in PDAPP mice without altering brain Aβ 
burden, suggesting a role for soluble Aβ in the cognitive impairments.  Nevertheless, 
more studies are still needed to understand better how these different Aβ species injure 
neurons and synapses in vivo.    
Finally, it should also be noted that the current transgenic mouse models of AD 
do not develop the full range of pathological features of AD, and that the mouse is a 
different species; thus one must be cautious when extrapolating the animal data to 
humans. One good example is also from the Aβ vaccination studies.  Whereas 
transgenic AD model mice tolerated the Aβ vaccination well, some AD patients 
developed brain inflammation after this treatment (however, in a recent study Aβ 
vaccination, under certain circumstances, was also shown to induce CNS inflammation 
in normal mice, Furlan et al., 2003).  Similarly, the results obtained from the present 
study may not entirely be applicable to AD patients; however, as an in vivo system, 
transgenic mice are still invaluable in exploring the pathological mechanisms of the 
disease and in testing novel therapeutics for treatment of AD. 
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7. CONCLUSIONS 
 
        – An increase in the levels of ACh, induced by long-term treatment with 
metrifonate, failed to inhibit the marked overproduction and deposition of Aβ in AP 
mice (I).   
        – Hippocampal APP and Aβ levels, and the extent of Αβ deposition were not 
increased by a non-selective cholinergic depletion resulting from the transection of the 
fimbria-fornix (II).   
Together, these findings do not support the notion derived from in vitro studies 
that ChEI treatment would slow down amyloid accumulation in the brain, or a putative 
role of cholinergic dysfunction in the promotion of Aβ production and deposition, but 
conversely they indicate that APP metabolism may not be regulated by or related to the 
levels of ACh, at least in the AP mice used in our studies.  However, considering the 
differences between AD mouse model and human patients, the potential role of altered 
ACh levels in the regulation of APP metabolism still need to be more carefully 
investigated in future studies. 
         – In AP mice, amyloid deposits are largely restricted to the hippocampal formation 
and the neocortex; few plaques, if any, are present in the thalamus, brainstem or 
cerebellum.  The earliest and densest depositions are present in the dorsal subiculum, 
which may underlie the selective impairment of hippocampal-dependent long-term 
spatial memory in AP mice (III).   
         – The impairment of spatial memory in AP mice is significantly correlated with 
the level of insoluble, but not that of soluble Αβ42, in the hippocampus.  The CSF Αβ42 
level appears not to be a suitable indicator of the cognitive decline, because it only 
correlates with the level of hippocampal soluble Αβ42 (IV).   
Taken together, these findings indicate an important role for insoluble Αβ42 in 
the memory dysfunctions in our AP mice.  As the characteristics of amyloid 
neuropathology and memory impairment in AP mice resemble the phenotype of early 
AD, this transgenic mouse line may provide a good model to examine the 
pathophysiological events leading to memory impairments in AD. 
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